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INTRODUCTION 
 A drug may be defined as a chemical substance, or combination of 
substances, administered for the investigation, prevention or treatment of 
diseases or symptoms, real or imagined. An adverse drug reaction (ADR) may 
be defined as an undesirable clinical manifestation resulting from administration 
of a particular drug; this includes reactions due to overdose, predictable side 
effects and unanticipated adverse manifestations. ADR can also be defined as 
‘an appreciably harmful or unpleasant reaction, resulting from an intervention 
related to the use of a medicinal product, which predicts hazard from future 
administration and warrants prevention or specific treatment, or alteration of the 
dosage regimen, or withdrawal of the product’. ADRs are underreported and are 
an underestimated cause of morbidity and mortality; it has been estimated that 
ADRs represent the fourth to the sixth leading cause of death[1],[2] 
 Adverse Cutaneous Drug Reactions (ACDRs) are probably the most 
frequent manifestations of all drug sensitivity reactions  although their incidence 
is difficult to determine. Very few published studies[3],[4] have assessed the 
epidemiological and clinical features of drug reactions in India and still fewer in 
South India[3]. Hence this study was undertaken to assess the pattern and clinical 
features of ACDRs  and common drugs causing them in South Tamil nadu. 
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AIM OF THE STUDY 
 
1. To study the clinicoepidemiological pattern of various adverse cutaneous drug 
reactions in patients attending SKIN OPD, Government Rajaji Hospital. 
 
2. To study the common drugs causing adverse cutaneous  drug reactions. 
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REVIEW OF LITERATURE 
EPIDEMIOLOGICAL ASPECTS OF ADVERSE CUTANEOUS DRUG 
REACTIONS: 
 Incidence: 
The exact incidence and prevalence of cutaneous adverse drug reactions  
are unknown, but the overall prevalence is believed to be less than 1% of the 
general population. Estimates between 2.0% to 2.4% have been reported 
worldwide.[68] Out of this 7% is due to antibiotics.  An incidence of 0.38% has 
been reported from India .[69] 
Immunosuppressed patients are most frequently affected.[1] 
Age: 
Though ADRs can affect any age group ADRs occur in 6–17% of children 
admitted to specialist paediatric hospitals ,those over 60 years of age comprise 
only 12% of the population in the USA, 33% of all drugs are prescribed for this 
age group,[1] [70] and the elderly have a significantly higher incidence of ADRs, 
related to decreased organ reserve capacity, altered pharmacokinetics and 
pharmacodynamics, and polypharmacy.  
Gender: 
Women are more likely than men to develop ADRs.[1] 
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Classification of adverse drug reactions:[1] 
Non-immunological 
  Predictable 
  Overdosage 
  Side effects   
  Cumulation 
  Delayed toxicity 
  Facultative effects 
  Drug interactions 
  Metabolic alterations 
  Teratogenicity 
  Non-immunological activation of effector pathways 
  Exacerbation of disease 
  Drug-induced chromosomal damage 
Unpredictable 
  Intolerance 
  Idiosyncrasy 
Immunological (unpredictable) 
IgE-dependent drug reactions 
Immune complex-dependent drug reactions  
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Cytotoxic drug-induced reactions  
Cell-mediated reactions 
Miscellaneous 
Jarisch–Herxheimer reactions 
Infectious mononucleosis–ampicillin reaction 
Criteria for assessment of potential drug reactions have been promulgated, and 
include:[64][65] 
1.recurrence on challenge;  
2.existence of a pharmacological basis for the reactions; 
3.the occurrence of immediate acute or local reactions at the time of 
administration,  
4.of previously known reactions with a new route of administration, or  repeated 
rare reactions; and  
5.the presence of immunological abnormalities .  
 
FIXED DRUG ERUPTION 
1. Age: 
Fixed drug eruptions have been reported in patients as young as 1.5 years and as 
old as 87 years. The mean age at presentation is 30.4 years in males and 31.3 
years in females.[43] 
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2. Gender : 
One large study of 450 patients by mahboob et al.[43] revealed a male to female 
ratio of 1:1.1 for fixed drug eruptions.  
3.Race: 
Fixed drug eruptions have no known racial predilection. A genetic susceptibility 
to developing a fixed drug eruption with an increased incidence of HLA-B22 is 
possible. [44] 
4. Pathophysiology: 
Although the exact mechanism is unknown, recent research suggests a cell-
mediated process that initiates both the active and quiescent lesions. The process 
may involve an antibody-dependent, cell-mediated cytotoxic response.  CD8+ 
effector/memory T cells play an important role in reactivation of lesions with re-
exposure to the offending drug[45] 
The offending drug is thought to function as a hapten that preferentially binds to 
basal keratinocytes, leading to an inflammatory response.  Through liberation of 
cytokines such as tumor necrosis factor-alpha, keratinocytes may locally up-
regulate expression of the intercellular adhesion molecule-1 (ICAM1).The up-
regulated ICAM1 has been shown to help T cells (CD4 and CD8) migrate to the 
site of an insult.  
The newly arriving and residential CD8 cells likely perpetuate tissue damage by 
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their production of the inflammatory cytokines interferon-gamma and tumor 
necrosis factor-alpha. CD8 cells isolated from active lesions have also been 
shown to express alpha E beta 7, a ligand for E-cadherin, which may further 
contribute to the lymphocyte’s ability to localize to the epidermis. Other cell 
surface molecules, such as CLA/alpha4beta1/CD4a, that bind E-selectin/vascular 
cellular adhesion molecule-2/ICAM1 help to further attract CD8 cells to the 
area.  
Changes in cell surface markers allow vascular endothelium to select CD4 cells 
for migration into active lesions. These regulatory CD4 cells likely produce 
interleukin 10, which has been shown to help suppress immune function, 
resulting in a resting lesion.As the inflammatory response dissipates, interleukin 
15 expression from keratinocytes is thought to help ensure the survival of CD8 
cells, helping them fulfill their effector memory phenotypes. Thus, when 
reexposure to the drug occurs, a more rapid response develops in the exact 
location of any prior lesions.[45] 
5.  History: 
The initial eruption is often solitary and frequently located on the lip or genitalia. 
Rarely, the eruption may be intraoral. Lesions are commoner on the limbs than 
on the trunk; the hands and feet, genitalia and perianal areas are favoured sites. 
Perioral and periorbital lesions may occur. Genital  and oral mucous membranes  
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may be involved in association with skin lesions, or alone. With the initial fixed 
drug eruption attack, a delay of up to 2 weeks may occur from the initial 
exposure of the drug to the development of the skin lesion.Skin lesions develop 
over a period of hours but require days to become necrotic. Lesions may persist 
from days to weeks and then fade slowly to residual oval hyperpigmented 
patches.[46] 
The eruption may initially be morbilliform, scarlatiniform or erythema 
multiforme-like; urticarial, nodular or eczematous lesions are less common. 
A fixed drug eruption characteristically recurs in the same site or sites each time 
the drug is administered; with each exposure, however, the number of involved 
sites may increase. Subsequent reexposure to the medication results in a 
reactivation of the site, with inflammation occurring within 30 minutes to 16 
hours. The reactivation of old lesions also may be associated with the 
development of new lesions at other sites. 
Patients may not be cognizant that a drug, nutritional supplement, over the 
counter medication, or, rarely, food (eg, fruits, nuts) triggered the skin problem. 
They may be convinced that an insect, particularly a spider, may be the culprit. 
A careful history is required to elicit the fact that a drug has been taken and is 
temporally related to the onset of the eruption. Medications taken episodically, 
such as pain relievers, antibiotics, or laxatives, are often to blame. When able to 
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be identified, patients often report ingestion of one the following types of 
medications:[67] 
• Analgesics 
• Muscle relaxants 
• Sedatives 
• Anticonvulsants 
• Antibiotics 
In the case of isolated male genital fixed drug eruption (often affecting only the 
glans penis), the drugs most commonly implicated in one series were co-
trimoxazole (trimethoprim– sulfamethoxazole), tetracycline and ampicillin . 
Cross-sensitivity to related drugs may occur, such as between phenylbutazone 
and oxyphenbutazone, between tetracycline type drugs, and between 
anticonvulsants .   
Local symptoms may include pruritus, burning, and pain.Systemic symptoms are 
uncommon, but fever, malaise, nausea, diarrhea, abdominal cramps, anorexia, 
and dysuria have been reported.  
Further questioning may reveal prior episodes of fixed drug eruption, atopic 
disease, or other past drug reactions. Family history may render a history of 
atopy, drug reactions, or diabetes mellitus.  
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Several cases of fixed drug eruption on the genitalia have been reported in 
patients who were not ingesting the drug but whose sexual partner was taking 
the offending drug and the patient was exposed to the drug through sexual 
contact.  
6. Types:  Several variants of fixed drug eruption have been described, based on 
their clinical features and the distribution of the lesions.These include the 
following:[47] 
• Pigmenting fixed drug eruption 
• Generalized or multiple fixed drug eruption 
• Linear fixed drug eruption 
• Wandering fixed drug eruption 
• Nonpigmenting fixed drug eruption 
• Bullous fixed drug eruption 
• Eczematous fixed drug eruption 
• Urticarial fixed drug eruption 
• Erythema dyschromicum perstans–like fixed drug eruption 
• Vulval & Oral fixed drug eruption 
7. Differential diagnosis: 
• Bullous Pemphigoid 
• Cellulitis 
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• Drug-Induced Bullous Disorders 
• Eczema 
• Erythema Annulare Centrifugum 
• Erythema Multiforme 
• Herpes Simplex 
• Lichen Planus 
• Lichen Planus Actinicus 
• Discoid lupus erythematoses  
• Pemphigus Vulgaris , Pityriasis Rosea 
• Postinflammatory Hyperpigmentation 
8. Complications: 
Hyperpigmentation is the most likely complication of a fixed drug eruption 
(FDE). The potential for infection exists in the setting of multiple, eroded 
lesions. Generalized eruptions have been reported following topical and oral 
provocation testing.[48] 
9. Prognosis: 
The prognosis is very good, and an uneventful recovery should be expected. No 
deaths due to fixed drug eruption have been reported. Residual 
hyperpigmentation is very common, but this is less likely with the 
nonpigmenting variant. As healing occurs, crusting and scaling are followed by 
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pigmentation, which may be very persistent and occasionally extensive, 
especially in pigmented individuals; pigmentation may be all that is visible 
between attacks.[49] 
 
MACULOPAPULAR RASH 
A drug reaction is suspected when a maculopapular eruption begins within 4 to 
12 days of beginning a new medicine. Macules predominate initially, then 
become confluent patches with papular areas within the patches.[17] 
Proposed mechanism :  
Morbilliform drug eruption is a non-immediate type IV allergic reaction 
involving drug-specific T cells (CD4+) with direct cytotoxic effects and release 
of pro-inflammatory factors.[1]  
Clinical features: Most reactions develop within 7 to 8 days, though reactions to 
aminopenicillins may develop over a longer period (>8 days) & in phenytoin it 
takes around 3 weeks . This interval is the time needed for an immunological 
(cell-mediated) delayed-type hypersensitivity reaction to occur.The eruption is 
characteristically polymorphic, with confluent areas on the trunk, papular areas 
on the arms, and purpuric areas on the feet.In maculopapular rash, features range 
from a normal epidermis to local areas of basal cell degeneration with 
eosinophilic infiltrat Dermis showed congested vessels, mild to moderate 
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perivascular/periappendageal infiltrate of mononuclear cells.[66] 
    Moderate pruritus, a low-grade fever, and general malaise may be present. 
Mucous membranes are typically spared, and lymphadenopathy is mild if 
present. 
The eruption generally fades over 1 to 2 weeks without complication. Post-
inflammatory desquamation is common. Antibiotics (sulphonamides, 
aminopenicillins, cephalosporins) and anticonvulsants are most commonly 
implicated.[17] 
 Chemotherapeutic agents, particularly cytarabine, dacarbazine, hydroxyurea, 
paclitaxel, and procarbazine, have also been associated with maculopapular 
eruption. Epidermal growth factor receptor inhibitors (EGFRs; e.g., cetuximab) 
also have a propensity to trigger cutaneous eruptions.  
Treatment: 
Prompt cessation of the causative drug results in resolution over 1-2 weeks. No 
specific treatment is required but topical corticosteroids or oral antihistamines 
may give symptomatic relief of itch.[17] 
 
URTICARIA 
Urticaria is a skin rash, also called hives, or nettle rash, which is often 
accompanied by swelling and itching of the skin. 
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Classification: 
-Immune-mediated  
  IgE-mediated: penicillin  
  Complement and immune complex mediated: penicillin, immunoglobulins, 
whole     blood. 
-Nonallergic urticarial ACDR  
Analgesics/NSAIDs inhibit/block cyclooxygenase in prostaglandin synthesis  
Radio contrast media 
ACE inhibitors: inhibition of kinin metabolism 
Calcium channel blockers  
Drugs releasing histamine[13] 
Clinical features:  
Time from Initial Drug Exposure to Appearance of Urticaria : IgE-Mediated 
Initial sensitization, usually 7–14 days; urticaria may occur while the drug is still 
being administered or after it is discontinued. In previously sensitized 
individuals, usually within minutes or hours. Skin Symptoms consist of Pruritus, 
burning of palms/ soles, auditory canal. With airway edema, difficulty breathing. 
Drug-induced urticaria  may be allergic (immunologically mediated) or 
pseudoallergic (nonimmunologically mediated). 
 Common drugs: Penicillins , Cephalosporins , Sulphonamides , Cytostatic 
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agents, ACE inhibitors, Calcium channel blockers 
Drug-induced urticaria is seen in association with anaphylaxis, angio-oedema 
and serum sickness.[9] 
Differential diagnosis : 
Is of acute edematous red pruritic plaque(s): 
a) Allergic contact dermatitis (poison ivy, poison oak dermatitis) 
b)  Cellulitis 
c)  insect bite(s). 
Management : 
The offending drug should be identified and withdrawn as soon as possible. 
Prevention: Previously Sensitized Individuals. The patient should carry 
information listing drug sensitivities (wallet card, bracelet). Radiographic 
Contrast Media Avoid use of contrast media known to have caused prior 
reaction. If not possible, pretreat patient with antihistamine and prednisone (1 
mg/kg) 30–60 min before contrast media exposure. 
Treatment of Acute Severe Urticaria/Anaphylaxis : 
Epinephrine : 0.3–0.5 mL of a 1:1000 dilution subcutaneously, repeated in 15–
20 min. Maintain airway, Intravenous access, Antihistamines H1 blockers or 
H2 blockers or combination. 
Systemic Glucocorticoids : Intravenous Hydrocortisone or methylprednisolone 
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for severe symptoms. Oral Prednisone 70 mg, tapering by 10 or 5 mg daily over 
1–2 weeks, is usually adequate.[13] 
 
ERYTHRODERMA 
It is most frequently caused by antibiotics, antiepileptic drugs and NSAIDs. [50] 
Drug-induced erythroderma accounts for about 10% of all erythrodermas.  
Definition: generalized erythema of the skin (more than 90% of the body surface 
area) accompanied by a variable degree of scaling.  
Pathogenesis: The rise in adhesion molecule expression (VCAM-1, ICAM-1, E-
selectin and P-selectin) seen in exfoliative dermatitis stimulates dermal 
inflammation, which may lead to epidermal proliferation and increased 
production of inflammatory mediators. The complex interaction of cytokines and 
cellular adhesion molecules such as interleukin-1, -2 and -8; intercellular 
adhesion molecule-I (ICAM-I); and tumor necrosis factor (TNF) results in 
significantly elevated epidermal turnover rate, leading to above normal mitotic 
rate. The amount of germinative cells increases and the transit time of 
keratinocytes through the epidermis decreases, causing loss of more cellular 
material from the surface. 
Clinical features:  
The pattern observed is erythematous patches, which increase in size and 
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coalesce to form extensive areas of erythema, and eventually spread to involve 
most of the skin surface.Some studies have shown sparing of the nose and 
paranasal areas, and this has been described as the "nose sign". 
The epidermis appears thin, giving a glossy appearance to the skin. Once 
erythema has been established, white or yellow scales develop that progress to 
give the skin a dry appearance with a dull scarlet and grey hue. Induration and 
thickening of the skin from edema and lichenification may provoke a sensation 
of severe skin tightness in the patient. The skin is bright red, dry, scaly and 
warm to touch.  
Some patients may experience involvement of their palms and soles, with hair 
loss and nail shedding. Involved nails are thick, lusterless, dry, brittle, and show 
ridging of the nail plate. Subungual hyperkeratosis, distal onycholysis, splinter 
hemorrhages occur; and sometimes, the nails may shed. Shelley described 
alternating bands of nail plate discontinuity and leukonychia in drug-induced 
erythroderma.  
Laboratory investigations: 
Laboratory findings in the erythrodermic patient are usually nonspecific. 
Common abnormalities are mild anemia, leukocytosis with eosinophillia, 
elevated sedimentation rate, decreased serum albumin, increased uric acid, 
abnormal serum protein electrophoresis with polyelevation in the gamma 
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globulin region and elevated IgE levels.  
Management: 
To identify & stop the offending drug. Systemic corticosteroids , nutritional 
replacement, fluid and electrolyte losses. Local skin care measures should be 
employed, such as oatmeal baths as well as wet dressings to weeping or crusted 
sites followed by the application of bland emollients and low potency 
corticosteroids. Known precipitants and irritants are to be avoided. 
 Secondary infections are treated with antibiotics. Edema in dependent areas, 
such as in periorbital and pedal areas, may require diuretics. 
 Hemodynamic or metabolic instability should be addressed adequately. Serum 
protein, electrolyte and blood urea levels should be monitored.[51] 
                               URTICARIA WITH ANGIOEDEMA 
In the past this was called giant urticaria or angioneurotic edema or Quincke's 
edema. Angioedema is a swelling of the deep layers of the subcutaneous or 
submucosal tissue or both. Most commonly it occurs on the lips, tongue, face, 
hands or feet. 
The oedema is caused by an increase in capillary leakage as a result of 
inflammatory mediators. This can be a manifestation of Type I allergic 
reactions; or a consequence of deficiency in C1-esterase inhibitor or because of 
failure to metabolise mediators such as bradykinin. Drugs are implicated in all 
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three mechanisms, although C1-esterase inhibitor deficiency is usually 
hereditary. 
Drug most commonly implicated:  
ACE-inhibitors , Bupropion , vaccines , selective serotonin reuptake inhibitors 
(SSRIs) , COX-II inhibitors , angiotensin II antagonists , other antidepressants , 
non-steroidal anti-inflammatory drugs (NSAIDs), statins , proton pump 
inhibitors. 
Management: 
Primary management is to ensure an adequate airway. Adrenaline, 
antihistamines, and corticosteroids may be needed. Endotracheal intubation or 
tracheotomy is required in severe cases.[52] 
DRESS 
[Drug Rash with Eosinophilia & Systemic Symptoms] 
Synonym:  
Drug Hypersensitivity Syndrome[DHS] 
 drug-induced delayed multiorgan hypersensitivity syndrome (didmohs) 
Definition: Long-lasting papulopustular or erythematous skin eruption often 
progressing to exfoliative dermatitis, with fever, lymphadenopathy, and visceral 
involvement (hepatitis, pneumonitis, myocarditis, pericarditis, nephritis). 
Incidence/prevalence:For phenytoin, carbamazepine, and phenobarbital, the 
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incidence of DRESS has been estimated to 1 reaction per 5,000 to 10,000 
exposures. 
Race:  Reactions to antiepileptic drugs may be higher in black individuals. 
Etiology:Most commonly: antiepileptic drugs (phenytoin, carbamazepine, 
phenobarbital; cross-sensitivity among the three drugs is common) and 
sulfonamides (antimicrobial agents, dapsone, sulfasalazine).  
Less commonly: allopurinol, gold salts, sorbinil, minocycline, zalcitabine, 
calcium-channel blockers, ranitidine, thalidomide, mexiletine. 
Pathogenesis :  
Some patients have a genetically determined inability to detoxify the toxic arene 
oxide metabolic products of anticonvulsant agents. Slow N-acetylation of 
sulfonamide and increased susceptibility of leukocytes to toxic hydroxylamine 
metabolites are associated with higher risk of hypersensitivity syndrome. 
Clinical manifestation: 
Onset  :  2–6 weeks after drug is initially used, and later than most other  serious 
skin reactions.  
Prodrome: Fever, rash ,malaise. 
Skin Lesions:  
Early :    Morbilliform   eruption  on face, upper trunk, upper extremities; cannot 
be distinguished from exanthematous drug eruption. May progress to 
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generalized exfoliative dermatitis/erythroderma, especially if drug is not 
discontinued. Eruption becomes infiltrated with edematous follicular 
accentuation. Facial edema (especially periorbitally) is characteristic. Dermal 
edema may result in blister formation. Sterile folliculocentric as well as 
nonfollicular pustules may occur. Eruption may become purpuric on legs. 
Scaling and/or desquamation may occur with healing.  
Distribution : Symmetric, almost always on trunk and extremities. Lesions may 
become confluent and generalized. 
Mucous Membranes: Cheilitis, erosions, erythematous pharynx, enlarged tonsils. 
 General Examination: Elevated temperature (drug fever). 
Lymph Nodes:Lymphadenopathy frequent ± tender; usually due to benign 
lymphoid hyperplasia. Involvement of liver, heart, lungs, joints, muscles, 
thyroid, brain also occurs. 
Laboratory examinations :  
Hemogram and Chemistries: Eosinophilia (30% of cases), Leukocytosis, 
Mononucleosis  like atypical lymphocytes. Signs of hepatitis and nephritis. 
Histology of  skin  shows Lymphocytic infiltrate, dense and diffuse or 
superficial and perivascular ± Eosinophils or dermal edema. In some cases, 
bandlike infiltrate of atypical lymphocytes with epidermotropism, simulating 
cutaneous T cell lymphoma. Benign lymphoid hyperplasia of lymph nodes. 
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Uncommonly  atypical  lymphoid hyperplasia, pseudolymphoma. 
Liver  - Eosinophilic infiltrate or granulomas. Kidney -Interstitial nephritis. 
The table given below indicates organ involvement in DRESS syndrome:[53] 
 
Incidence of organ involvement in DRESS syndrome  
Organ Percent of patients with involvement 
Liver 80% 
Kidney 40% 
Pulmonary 33% 
Cardiac/muscular 15% 
Pancreas 5% 
Incidence of hematologic abnormalities in DRESS syndrome  
Abnormality Percent of patients with abnormality 
Atypical lymphocyte 63% 
Eosinophilia 52% 
Lymphocytopenia 45% 
Thrombocytopenia 25% 
Lymphocytosis 25% 
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Diagnosis: 
Proposed Diagnostic Criteria:[54] 
(1) Cutaneous drug eruption;  
(2) hematologic abnormalities (eosinophilia >1500/μL or atypical lymphocytes); 
 (3) systemic involvement [adenopathies >2 cm in diameter or hepatitis (SGOT 
>2 N) or interstitial nephritis or interstitial pneumonitis or carditis]. Diagnosis is 
confirmed if three criteria are present. 
Differential diagnosis : 
Early:  That of morbilliform eruptions, can mimic early measles or rubella.  
Later:  Serum sickness, drug-induced vasculitis,  Henoch-Schönlein purpura, 
cryoglobulin-associated vasculitis, vasculitis associated with infection, and 
collagen vascular diseases. 
Rash Plus Lymphadenopathy :  Rubella,  primary EBV  or CMV mononucleosis 
syndrome. 
Course and prognosis: 
Rash and hepatitis may persist for weeks after drug is discontinued. In patients 
treated with systemic glucocorticoids, rash and hepatitis may recur as 
glucocorticoids are tapered. Lymphadenopathy usually resolves when drug is 
withdrawn; however, rare progression to lymphoma has been reported. Rarely, 
patients die from systemic hypersensitivity such as with eosinophilic 
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myocarditis. Clinical findings recur if drug is given again. 
Management: 
Identify and discontinue the offending drug.  
Symptomatic Treatment : 
 Oral antihistamine to alleviate pruritus. 
Glucocorticoids : 
Topical High-potency topical glucocorticoids applied twice a day are usually 
helpful in relieving cutaneous symptoms of pruritus but do not alter systemic 
hypersensitivity. 
Systemic : Prednisone (0.5 mg/kg per day) usually results in rapid improvement 
of symptoms and laboratory parameters. [54] 
Future Drug Therapy:  
Cross-sensitivity between various aromatic antiepileptic drugs occurs, making it 
difficult to select alternative anticonvulsant therapy. 
Prevention: 
The individual must be aware of his or her specific drug hypersensitivity and 
that other drugs of the same class can cross-react. These drugs must never be 
readministered. Patient should wear a medical alert bracelet. 
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STEVEN JOHNSON SYNDROME 
 SJS is a severe illness of usually sudden onset, associated with marked 
constitutional symptoms of high fever, malaise, myalgia, arthralgia and 
extensive erythema multiforme of the trunk, with occasional skin blisters and 
erosions covering less than 10% of the body’s surface area. [1] 
The skin lesions are variable in extent, and consist of typical maculopapular 
lesions of erythema multiforme, bullous or, rarely, pustular lesions. New crops 
of lesions develop over a period of 10 days, or sometimes 3–4 weeks. Mucous 
membranes: 
 Oral: extensive bulla formation,  erosions and a greyish white membrane, 
so that the mouth and lips show characteristic haemorrhagic crusting . [7] 
 Eyes: a severe catarrhal or purulent conjunctivitis can be seen. Corneal 
ulceration, anterior uveitis or panophthalmitis may occur. The eye 
changes often regress completely, but synechiae, corneal opacities and 
rarely blindness are possible sequelae.  
 Genital : retention of urine due to involvement of the bladder. [1] 
Respiratory symptoms may occur, and often the radiological changes within the 
lungs are far greater than the symptoms. Abnormalities of liver function may be 
present. Renal involvement with haematuria or even renal tubular necrosis has 
been reported and may lead to progressive renal failure. [25] 
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Untreated, this disease used to have a mortality of 5–15% from infection, 
toxaemia or renal damage, but the mortality rate is now lower. The eruption 
usually heals without sequelae, although the eyes may be permanently damaged. 
Eruptive melanocytic naevi are reported to develop after SJS. 
Complications : 
Acute: Massive fluid and electrolyte loss (3–4L/day) ,prerenal renal 
failure,Bacterial infection and septicaemia, hypercatabolism: insulin resistance, 
diffuse interstitial pneumonitis, mucous membrane involvement 
Chronic :Ocular complications (up to 35%) Conjunctivitis, ectropion or 
entropion, corneal scarring , Symblepharon,Sjögren-like sicca syndrome  
Other mucous membrane involvement :Oesophageal stricture ,Phimosis. Vaginal 
synechiae, Orogenital ulcers 
Miscellaneous: Wound infection, pigmentary changes, nail dystrophy, 
hypohidrosis, scarring alopecia, contractures, development of melanocytic 
naevi.[1] 
Management is similar to toxic epidermal necrolysis and has been discussed 
subsequently. 
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TOXIC EPIDERMAL NECROLYSIS 
TEN: The incidence of erythema multiforme, SJS and TEN was estimated at 1.8 
cases per million person years for patients aged between 20 and 64 years; the 
incidence for patients aged less than 20 years, and 65 years or more, increased to 
7 and 9 cases per million person-years, respectively. The incidence of TEN was 
estimated at 0.5 per million per year.[1] 
Aetiology 
Immunology 
In general, CD4 T cells predominate in the upper dermis, while epidermal CD8 
T cells and macrophages are variable and Langerhans’ cells virtually disappear. 
Keratinocytes express HLA-DR and ICAM-1, and there is endo- thelial cell 
ICAM-1, vascular cell adhesion molecule 1 (VCAM-1) and E-selectin 
expression. CD3 activated T cells expressing the skin-homing receptor 
(cutaneous leukocyte antigen; CLA) in both skin and peripheral blood parallel 
the severity of the disease, and tumour necrosis factor-α (TNF-α), IFN-γ and 
interleukin-2 (IL-2) are overexpressed in peripheral blood mononuclear cells, 
suggesting an important role for T cells in TEN . Prominent involvement of the 
monocyte–macrophage lineage, including factor XIIIa, HLA-DR, dendrocytes 
and CD68, Mac387, macrophages, before, during and especially after epidermal 
necrosis has been reported ,with dense labelling of the epidermis for TNF-α.  
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Mechanisms mediating keratinocyte death: 
 Cytokines released by activated lymphocytes and/or from keratinocytes 
may contribute to apoptosis  in TEN. Activated lymphocytes may induce 
apoptosis via an interaction between Fas-ligand (FasL), expressed on the surface 
of and secreted by lymphocytes, and Fas antigen (CD95), expressed by 
keratinocytes after exposure to IFN-γ. There is keratinocyte overexpression of 
Fas antigen in drug-induced erythema multiforme, SJS and TEN . Moreover, 
peripheral blood mononuclear cells from TEN and SJS patients secreted high 
levels of soluble(s) FasL on stimulation with the causal drug . Increased sFasL 
levels precede skin detachment in patients with SJS and TEN . Bcl-2, a protein 
known to block apoptosis, is strongly expressed along the basal layer and in the 
dermal infiltrate both in erythema multiforme and SJS/TEN; thus Fas-mediated 
cell death may be partially suppressed by Bcl-2 protein . 
The matrix metalloproteinase MMP2 has a significant role in epidermal 
detachment, inflammation and re-epithelialization.  
Drugs implicated in toxic epidermal necrolysis :  
 Antibiotics: Sulphonamides : Co-trimoxazole , Sulfadoxine, Sulfadiazine,  
       Sulfasalazine 
          Penicillins : Amoxicillin  Ampicillin 
                Cephalosporins 
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 Non-steroidal anti-inflammatory drugs : 
       Phenylbutazone 
       Oxyphenabutazone  
       Oxicam-derivatives 
Clinical features:  
Typically sheet  like erosions involve more than 30% of the body surface with 
widespread purpuric macules or flat atypical target lesions, and there is severe 
involvement of conjunctival, corneal, irideal, buccal, labial and genital mucous 
membranes.[27] 
Prodromal period: Flu-like symptoms (malaise, fever, rhinitis and 
conjunctivitis), sometimes accompanied by difficulty in urination, which usually 
lasts 2–3 days; however, it may last from 1 day to 3 weeks before signs of skin 
involvement develop. 
Acute phase : Persistent fever, severe mucous membrane involvement and 
generalized epidermal sloughing to leave large, raw, painful areas, and lasts 
from 8 to 12 days. There may be an initial ‘burning’ maculopapular, urticarial or 
erythema multiforme-like eruption. Most frequently, the initial individual skin 
lesions form poorly defined macules with darker purpuric or blistering centres, 
progressively merging on the chin, upper parts of chest and back. 
Nikolsky’s sign, the ability to extend the area of superficial sloughing by gentle 
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lateral pressure on the surface of the skin at an apparently unaffected site, may 
be positive. 
Detachment of the full thickness of the epidermis at sites of pressure or trauma, 
such as the back, shoulders or buttocks, leaves a dark red oozing dermis.  
However, the entire skin surface may be involved, with up to 100% of the 
epidermis sloughing off. Only the hairy portion of the scalp is never affected. 
The process tends to occur in waves, over a 3- to 5-day period (sometimes a 
week), but involvement of the whole of the body surface occurs within 24 h in 
approximately 10% of cases. 
Mucous membranes (particularly the buccal, and less commonly the 
conjunctival, genital, perianal, nasal, tracheal, bronchial, pharyngeal and 
oesophageal membranes) are involved in nearly all patients (85–95%). Urethritis 
develops in up to two-thirds of patients, and may lead to urinary retention. 
Stomatitis and mucositis lead to impaired oral intake with consequent 
malnutrition and dehydration. Intestinal involvement has been documented . 
Healing occurs by re-epithelialization; this may occur within a few days on the 
anterior thorax, but is slower on the back and at intertrigi- nous areas. Most 
patients’ skin lesions are completely healed in about 3–4 weeks, but mucosal 
lesions take longer and the glans penis may take up to 2 months to heal over. 
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Investigations:  
Increase in serum aminotransferases and serum amylase  overt hepatitis.  
Anaemia and lymphopenia with a selective and transient depletion of CD4+ T 
lymphocytes. Neutropenia is observed in approximately 30% of patients, and 
thrombocytopenia in 15%; eosinophilia is very unusual. Hypophosphataemia , 
hyperglycaemia,raised urea and creatinine levels, subclinical interstitial oedema 
is often noted on early chest X-rays.[1] 
Prognosis : 
There is an appreciable mortality as a result of TEN, increasing from 5% in SJS, 
to 10–15% in transitional SJS–TEN and 30–40% in TEN. 
SCORTEN prognosis score:[1] 
Parameters: 
1.Age > 40 years 
2.Presence of a malignancy  
3.Epidermal detachment > 30%  
4.Heart rate > 120/min 
5.Bicarbonate < 20 mmol/L 
6.Urea > 10 mmol/L  
7.Glycaemia > 14 mmol/L 
 1 point awarded for each parameter; SCORTEN derived by totalling scores[1] 
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SCORTEN                                                         Probability of death (%) 
0–1                                                                                     3 
 2                                                                                        12 
 3                                                                                        35 
 4                                                                                    58 
≥5                                                                                     90 
Management of toxic epidermal necrolysis:[1] 
Intensive therapy or burns unit, air-fluidized bed,analgesia, maintain fluid and 
electrolyte balance (replace up to 5 L/day), maintain body temperature, maintain 
nutrition, oral hygiene.  
Frequent ophthalmological assessment :Antiseptic/antibiotic eye drops 2hourly, 
disrupt synechiae frequently, limitation of infection 
Frequent cultures of erosions, and blood cultures, Culture tips of Foley catheters 
and intravenous lines, Prophylactic broad-spectrum systemic antibiotics 
(controversial).Topical cleansing/antibacterial agents 0.5% silver nitrate solution 
on gauze or 10% chlorhexidine gluconate washes orsaline washes or 
polymixin/bacitracin or 2% mupirocin, wound care :Paraffin gauze or hydrogel 
dressings ,biological dressings (xenografts, allografts, skin substitutes). Recently 
plasmaphereses and Intravenous immunoglobulins are being used. 
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ERYTHEMA MULTIFORME 
Erythema multiforme is an acute, self-limited, and sometimes recurring skin 
condition that is considered to be a type IV hypersensitivity reaction associated 
with certain infections, medications, and other various triggers. 
Erythema multiforme may be present within a wide spectrum of severity. The 
papules evolve into pathognomonic target lesions or iris lesions that appear 
within a 72-hour period and begin on the extremities . Lesions remain in a fixed 
location for at least 7 days and then begin to heal. 
The clinical description is as follows:[8] 
• Erythema multiforme minor - Typical target or raised, edematous papules                              
  distributed acrally. 
• Erythema multiforme major - Typical targets or raised, edematous papules  
    distributed acrally with involvement of one or more mucous membranes;    
    epidermal detachment involves less than 10% of total body surface area. 
Erosions of the oral mucosa may result in difficulty in eating, drinking, or 
opening the mouth. Conjunctival involvement may cause lacrimation, 
photophobia, burning eyes, or visual impairment. Genital lesions are painful and 
may result in urinary retention; painful micturition due to genitourinary tract 
ulceration may also occur. Shortness of breath or difficulty in breathing may 
occur due to tracheobronchial epithelial involvement. 
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Drug hypersensitivity: 
The keratinocyte is the ultimate target of this disease process, with keratinocyte 
necrosis being the earliest pathologic finding. 
Patients frequently display an altered metabolism of the responsible drug, and 
are considered to be slow acetylators, both genotypically and phenotypically.  
Drug metabolism is directed toward the alternative pathway of oxidation by the 
cytochrome P-450 system, resulting in increased production of reactive and 
potentially toxic metabolites. Affected individuals have a defect in the ability to 
detoxify these reactive metabolites, which may then behave as haptens by 
binding covalently to proteins on the surface of epithelial cells. This may then 
induce the immune response, leading to the severe skin reaction.[17] 
Sulfa drugs are the most common triggers (30%) followed by  the 
anticonvulsants, including barbiturates, carbamazepine, phenytoin, and valproic 
acid. 
Causative antibiotics include penicillin, ampicillin, tetracyclines, amoxicillin, 
cefotaxime, cefaclor, cephalexin, ciprofloxacin,erythromycin, minocycline, 
sulfonamides, trimethoprim-sulfamethoxazole, and vancomycin. 
Other drugs : albendazole, arsenic, bromofluorene, quinine, cimetidine, 
clofibrate, corticosteroids, diclofenac, didanosine, dideoxycytidine, 
diphosphonate, estrogen, etretinate, fluconazole, gabapentin, granulocyte-
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macrophage colony-stimulating factor (GM-CSF), hydralazine, indapamide, 
indinavir, mefloquine, methotrexate, meprobamate, mercurials, minoxidil, 
nifedipine, nevirapine,  nystatin, nonsteroidal anti-inflammatory drugs 
(NSAIDs), phenolphthalein,pyritinol, progesterone, potassium iodide, sulindac, 
suramin, saquinavir, thiabendazole, thiouracil, terbinafine, theophylline, 
verapamil, and dihydrocodeine phosphate.[13] 
Two additional rare clinical forms of erythema multiforme have been      
reported: [8] 
i) Continuous erythema multiforme manifests as a prolonged course with 
overlapping attacks and may be associated with systemic administration of 
glucocorticoids. 
ii) Persistent erythema multiforme has a protracted clinical course over months, 
is commonly associated with atypical skin lesions and is commonly resistant to 
conventional treatment. It has been reported in association with inflammatory 
bowel disease (IBD), occult renal carcinoma, persistent or reactivated Epstein-
Barr virus (EBV) infection, and HSV infection. 
 
 
 
 
42 
 
ACNEIFORM ERUPTIONS 
     This pattern of eruption represents a small percentage of drug-induced skin 
eruptions. Clinically it presents as a papulo-pustular inflammatory eruption on 
the face and upper trunk resembling acne vulgaris. 
 Drug-induced acne should be considered if : 
• The onset is sudden 
• There is worsening of existing acne 
• Comedones are absent 
• Monomorphic appearance of the papules and pustules 
• There is an exposure to a potentially responsible drug 
Few drugs can cause acneiform eruption historically, corticosteroids have been a 
common cause. However, the new EGF receptor (EGFR) antagonists used in 
cancer treatment, such as erlotinib, are associated with an acneiform eruption 
that carries a good prognostic factor for the treatment of the underlying 
condition as evidence of effect on another organ that expresses EGFR. 
Withdrawal of the culprit drug and treatment with tetracycline or erythromycin 
antibiotics is often all that is needed in terms of treatment[13]. 
    Adrenocorticotrophic hormone (ACTH), corticosteroids , dexamethasone in 
neurosurgical patients, anabolic steroids for body building , androgens (in 
females), oral contraceptives, iodides and bromides may produce acneiform 
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eruptions.  
Isoniazid may induce acne, especially in slow inactivators of the drug . Other 
drugs implicated in the production of acneiform rashes include dantrolene , 
danazol , quinidine , lithium  and azathioprine.[14] 
    The fact that acneiform eruptions do not affect prepubertal children indicates 
that previous hormonal priming is a necessary prerequisite. In cases in which the 
offending agent cannot be discontinued topical tretinoin may be helpful[17]. 
 
DRUG INDUCED PHOTOSENSITIVITY 
Phototoxic reactions :  Ultraviolet light activates the photosensitizing drug to 
emit energy that may damage adjacent skin tissue resulting in an intensified 
sunburn with skin peeling. Factors influencing the intensity and incidence of 
drug-induced phototoxicity include:  
1) the concentration, absorption, and pharmacokinetics of the drug. Higher doses 
of lipophilic drugs (e.g., amiodarone) known to cause this reaction have a higher 
incidence, and 
 2) the “dose” of sunlight (i.e., quantity and spectrum of sunlight). 
Phototoxicity is characterized by a rapid onset of erythema, pain, prickling, or 
burning sensation of areas exposed to the sun, with peak symptoms occurring 
12-24 hours after the initial exposure. The hallmark of this reaction is the 
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appearance of a sunburn-like reaction on areas of skin with the greatest exposure 
to sunlight. These reactions do not involve the immune system; therefore, prior 
exposure or sensitization to a drug is not necessary for this reaction to occur.[58] 
Photoallergic reactions :  
 Drug induced photoallergy is less common than phototoxicity, and requires 
prolonged or prior exposure to the photosensitizing drug. As the name suggests, 
this type of reaction is immune mediated. UV light reacts with the drug to 
produce an immunogenic stimuli known as a hapten. This hapten combines with 
a tissue antigen producing a cell mediated immune response resulting in a skin 
reaction. This reaction requires a latency period following drug exposure for the 
immunological memory response to develop after the first drug contact. 
Subsequent exposures to the drug can elicit a more rapid reaction. Photoallergic 
reactions are not dose dependent. 
Photoallergic reactions are characterized by solar urticaria with eczema-like 
dermatitis and erythema. Light exposed areas on the skin are the predominant 
location of the reaction. These eruptions usually disappear spontaneously upon 
removal of the offending drug.[58] 
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LICHENOID DRUG ERUPTIONS 
Commonly caused due to HMG CoA reductase inhibitors , gold salts, beta 
blockers, antimalarials, thiazide diuretics, furosemide, spironolactone, and 
penicillamine.[59] 
Clinicalfeatures: 
• Extensive rash distributed symmetrically over the trunk and limbs 
• Photodistribution – the rash is predominantly in areas exposed to the sun 
• Rash may be scaly resembling eczema or psoriasis 
• Wickham’s  striae are usually absent 
• Nail and mucous membrane (e.g., mouth) involvement is uncommon  
• More likely to resolve leaving marked pigmentation 
Prevention and Treatment : [59] 
To stop the underlying offending drug  
1. Topical steroids such as clobetasol propionate and betamethasone 
propionate   ointments . 
2.  Hydrocortisone foam can be used. 
3. Steroid injections into affected areas may be useful for localised disease.   
4. Systemic steroids may also be used. 
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 ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS [AGEP]  
It is characterized by the rapid appearance of many pustules, which are sterile 
and located subcorneally in the epidermis; the patients have fever, leukocytosis, 
and sometimes also an eosinophilia. In >90% of the cases it is caused by drug 
intake, in particular aminopenicillins, anticonvulsants and anti-inflammatory 
drugs. Lethality in AGEP is 1% for older patients. 
The most striking feature of AGEP is the short interval between the drug 
administration and the onset of the disease.[60] 
The main histopathological findings in AGEP are spongiform superficial 
pustule, papillary edema, polymorphous perivascular infiltrate with eosinophils 
and leucocytoclastic vasculitis with fibrinoid deposits. 
Use of systemic steroid in AGEP is justified.[60]   
                             
TOXIC ACRAL ERYTHEMA 
Acral erythema is also known as palmoplantar erythrodysesthesia or hand-foot 
syndrome. It manifests as painful erythema  of the palms and soles, with or 
without bullae. These symptoms can be preceded by dysaesthesia . The pain 
from this rash may be so severe that daily activities are limited. If recognised 
early, the usual course of acral erythema is desquamation  followed by re-
epithelialization. The exact mechanism is unknown, but it is postulated that the 
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skin of the hands and feet favour a higher level of certain chemotherapy drugs 
which causes direct toxicity to the skin cells.[61] 
Associated drugs include: Cytarabine , Docetaxel , Doxorubicin , Fluorouracil, 
Cyclophosphamide , Daunorubicin , Vincristine , Vinblastin. 
 
DRUG INDUCED SWEET’S SYNDROME LIKE ERUPTION 
It is  rare and represent overall less than 5% of all cases. Approximately 50 cases 
have been reported, mostly as isolated clinical cases. Sitjas et al[62].  observed in 
a retrospective study of 30 patients with SS that 7 of them had received a new 
treatment before the rash occurred (non-steroidal anti-inflammatory drugs 
(NSAIDS), penicillin, carbamazepine). However, these drugs were often given 
for another confounding cause, especially an infection. 
Delay is highly variable, ranging from several days to, exceptionally, 2 years , 
but mostly within 7 days. Clinical presentation and histology are quite similar to 
the idiopathic form. Hyperleucocytosis could be less frequent during the drug-
induced form. Evolution is favourable after drug withdrawal. Fever vanishes 
within one to three days, eruption within 3–30 days under corticosteroid 
ointment and one week with oral corticosteroid therapy. Relapses occur in case 
of drug reintroduction.[62] 
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CUTANEOUS REACTIONS TO ANTINEOPLASTIC AND 
CHEMOTHERAPEUTIC DRUGS 
Alopecia: is the most common adverse skin manifestation of the 
chemotherapeutic treatment. There are two types of drug-induced alopecia: the 
anagen effluvium and the telogen effluvium. In the anagen effluvium hair loss 
occurs due to the sudden interruption of the mitotic activity of the hair matrix, 
one to two weeks after the start of chemotherapy, leading to lack of hair 
production or its thinning (Pohl- Pinkus constrictions). They involve the hair, 
eyebrows, beard, axillary and pubic hair. It is dose-dependent and reversible. In 
the telogen effluvium, hairs move prematurely to a resting phase with 
subsequent loss of normal hair.[40] 
The antineoplastic agents that most frequently cause the anagen effluvium lead 
to diffuse hair loss, of sudden onset, from 7 to 10 days after the start of 
chemotherapy.  Hair loss becomes more pronounced about 1 to 2 months after 
the start of treatment. 
Trichomegaly and hair curling : 
Hair alterations with acceleration of growth and shaft changes are observed with 
the use of epidermal growth factor receptor inhibitors (EGFR) 
Ungual, subungual, and periungual alterations : 
Nail alterations can present with a reduction of the nail growth speed, fragility, 
49 
 
lines of discoloration (Mees' lines), transverse depressions (Beau's lines), 
hyperpigmentation, onycholysis with subungual aseptic abcesses, 
photoonycholysis, paronychia, and pyogenic granulomas of the periungual folds. 
Hyperpigmentation can occur due to the use of cyclophosphamide, hydroxyurea, 
fluoropirimidines, such as 5-fluorouracil (5-FU) and specially anthracyclines 
like doxorubicin and daunorubicin . Painful onycholysis and subungual abcesses 
are due to the use of taxanes (docetaxel/paclitaxel) and anthracyclines 
(doxorubicin). Ingrown nails, paronychia, and pyogenic granuloma are 
associated with the use of tyrosine kinase inhibitors of the epidermal growth 
factor receptor (EGFR), such as erlotinib and gefitinib. The fenestration or 
avulsion of the lamina should be considered when abscesses that involve more 
than 50% of the nail bed are present.[40] 
Other adverse effects are as follows : 
Neutrophilic eccrine hidradenitis  
Eccrine squamous syringometaplasia  
Acral erythema or palmoplantar erythrodysesthesia syndrome  
Toxic erythema caused by chemotherapeutic drugs  
Acneiform eruption  
Mucous membrane alterations 
Stomatitis 
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DRUG INDUCED PSEUDOLYMPHOMA SYNDROME 
Pseudolymphoma syndrome (PS) consists of the triad of fever, generalised rash 
and lymphadenopathy. In addition malaise, hepatosplenomegaly, arthralgia, 
congestive cardiac failure, eosinophilia, thrombocytopenia and blood dyscrasias 
may be present. 
 Diphenylhydantion,  tridione and phenobarbitone etc. can produce a peculiar 
response of reticuloendothelial system resulting in PS.PS may be either 
hypersensitivity reaction or possibly a genetically determined enzymatic defect 
as seen in primaquin sensitivity. PS may present as generalised exfoliative 
dermatitis. PS may have generalised or localised lesions and may result from 
non-anticonvulsant drugs. Histopathology may reveal mycosis fungoides or 
sezary like syndrome.[63] 
 
DRUG INDUCED BULLOUS DISORDER 
Approximately 10% of cases of pemphigus are drug-induced or drug-triggered. 
The skin lesions are flaccid blisters which break easily and often only erosions 
+/- crusting are seen. The Nikolsky sign can be positive. In drug-induced 
pemphigus, mucous membranes are only involved in 10-15% of cases whereas 
drug-triggered pemphigus is indistinguishable from classic pemphigus.[57] 
Skin biopsy shows the typical separation of individual skin cells seen in 
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pemphigus. Direct immunofluoresence is positive in 90% of drug related 
pemphigus, compared to 100% in idiopathic classic disease. Circulating 
antidesmoglein autoantibodies are only detected in the blood in 70% of drug-
induced pemphigus. 
The onset of drug related pemphigus can be weeks to months after the drug was 
started. Resolution occurs after drug withdrawal in drug-induced pemphigus but 
not if drug-triggered. 
Drug-induced pemphigus is caused by drugs with a thiol group such as: 
D-penicillamine , Captopril ,Gold sodium thiomalate , Pyritinol 
Drug-triggered pemphigus follows nonthiol drug use including: 
Antibiotics especially betalactams, rifampicin , Pyrazolone derivatives , 
Nifedipine , Propranolol , Piroxicam, Phenobarbital.[57] 
 
DRUG INDUCED LUPUS ERYTHEMATOSUS 
Drug-induced lupus erythematosus is an autoimmune disorder  that is brought on 
by a reaction to medication.The most common medications known to cause 
drug-induced lupus include: isoniazid, hydralazine, and procainamide.[56] 
 Other medications known to cause drug-induced lupus, include: 
Anti-seizure medications , Capoten , Chlorpromazine , Etanercept, Infliximab , 
Methyldopa , Minocycline , Penicillamine ,Quinidine , Sulfasalazine 
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Symptoms tend to occur after taking the drug for at least 3 to 6 months. 
Persons with drug-induced lupus erythematosus may have symptoms that affect 
the joints (arthritis), heart, and lungs. Other symptoms associated with SLE, 
such as lupus nephritis and nervous system (neurological) disease, are rare.[56] 
DRUG INDUCED PSEUDOPORPHYRIA 
Skin signs include skin fragility and photosensitivity. Tense blisters form at the 
sites of minor trauma on sun exposed skin, bursting early to leave scabs and 
erosions. The blisters are most often seen on the hands and feet. They sometimes 
heal with some scar formation and milia.A sunburn type rash may also occur.[55] 
Pseudoporphyria is due to drugs which interact with sunlight to cause a 
phototoxic reaction in the skin. These include:[55] 
• Non steroidal anti-inflammatory drugs e.g. naproxen 
• Antibiotics: doxycyline, nalidixic acid 
• Diuretics: chlorthalidone, bumetanide, furosemide and hydrochlorthiazide  
• Retinoids – isotretinoin, etretinate, acitretin 
• Oral contraceptives 
It is important to withdraw the suspected agent where possible and avoid 
unnecessary exposure to strong light.Sun protection measures may include UVB 
and UVA blocking sunscreens.Symptoms usually resolve within several weeks 
but sometimes they are persistent.[55] 
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MATERIALS AND METHODS 
 This study was a prospective, observational study conducted at the skin 
OPD, Government Rajaji Hospital, Madurai Medical College, Madurai during 
the period from October 2009-September 2011[24 months]. 
Inclusion criteria: 
All consecutive consenting patients diagnosed clinically as a case of 
adverse cutaneous drug reaction of all age groups, of all genders, during the 
study period were included in the study. 
Exclusion criteria:  
Non consenting patients, and patients with morphological pattern of 
adverse cutaneous drug reaction, but were unable to provide an exact history of 
drug intake. 
Patients satisfying the criteria were included in the study and demographic 
details were recorded. A detailed clinical history including duration, site of 
onset, symptoms, drug history, family history were elicited. A complete general 
examination, systemic examination and dermatological examination were made. 
Digital photographs were taken.The morphology and distribution of skin lesions, 
concomitant affection of mucosa, hair, nails, palms, soles, genital involvement 
was meticulously recorded and presence of any other associated diseases were 
noted. 
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OBSERVATIONS AND RESULTS: 
1. Incidence of ACDRs :  Out of 1,03,536 patients who attended SKIN OPD 
during the study period of 24 months a total of 163 patients diagnosed with 
ACDR, fulfilling the inclusion criteria were included in the study. 0.15% was 
the overall incidence of ACDR during this period found in this study. 
2) Occurrence of various clinical types of ACDRs :  
      Table 1 : Clinical types of ACDRs: 
 
 
 
 
 
 
 
 
(FDE - Fixed Drug Eruption , URT – Urticaria , URT+A - Urticaria + angioedema , DRESS - Drug Rash with 
Eosinophilia and SystemicSymptoms , TEN - Toxic Epidermal Necrolysis , SJS - Steven Johnson Syndrome , 
ED - Erythroderma , MPR - Maculopapular Rash , EMF - Erythema Multiforme , AE - Acneiform Eruption ,  
PR – Phototoxic reaction) 
The most common drug eruption observed is FDE-84cases (51.53%). The other 
common types of drug eruptions include urticaria (9.25%), Maculopapular rash 
SI.No Clinical types of drug eruption Total no. of cases 
1. FDE 84 
2. Urticaria 15 
3. Maculopapular rash 15 
4. Erythroderma 11 
5. Urticaria+Angioedema 10 
6. DRESS 7 
7. SJS 7 
8. TEN 6 
9. EMF 5 
10. Acneiform eruptions 2 
11. Phototoxic reaction 1 
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4) Gender distribution in ACDRs: 
Table 3: Gender distribution in various ACDRs 
 
There were a total of 82 male and 81 female cases with a gender ratio of 1.01:1. 
The gender distribution for various drug eruptions is shown in Table 3. 
As show in table 3 male patients constituted 43 cases of FDE, 8 cases of 
urticaria, 8 cases of MPR, 5 cases of ED, 2 cases of urticaria with angloedema. 3 
cases of DRESS, 4 cases of TEN, 5 cases of SJS, 2 cases of EMF, 1 case of AE. 
Female patients constituted 41 cases of FDE, 7 cases of urticaria, 7 cases of 
MPR, 6 cases of ED, 8 cases of urticaria with angloedema. 4 cases of DRESS, 2 
cases of TEN, 2 cases of SJS, 3 cases of EMF, 1 case of AE, 1 case of PR. 
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5) Site of involvement in various types of ACDRs : 
Table 4 : Site of involvement in various types of ACDRs 
Site of 
involvement 
FDE URT MPR ED U+A DRESS TEN SJS EMF AE PR
Skin 
involvement 
only 
48 15 10 6 - 2 - - - 2 1 
Both skin &  
mucosal 
involvement 
36 - 5 5 10 5 6 7 5 - - 
Oral 
mucosa 
only 
25 - 5 5 5 5 - - 2 - - 
Genital 
mucosa 
only 
5 - - - - - - - - - - 
Both 
mucosae 
6 - - - 5 - 6 7 3 - - 
As seen in table 4 out of total 163 patients 84 [51.53%] cases had only cutaneous 
involvement without involving the mucosa but 79 [48.46%] cases had both skin 
and mucosal involvement. In patients having both skin and mucosal 
involvement, 47[59.49%] cases had oral mucosal involvement only, 5[6.32%] 
had genital mucosal involvement  only & 27[57.44%] had both oral and genital 
mucosal involvement. 
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7)Various drug classes involved in ACDRs: 
Table 6 : Various drug classes involved in ACDRs 
 
 
SI.N
o 
DRUG CLASS SUBCLASS DRUGS 
 
 
1. 
 
 
ANTIMICROBIALS 
 
Antibacterials 
Cotrimoxazole, 
Amoxycillin, Doxycycline, 
Ciprofloxacin, Cefixime, 
Cefoperazone, Dapsone, 
Norfloxacin, penicillin, 
Antituberculous regimen 
Antifungals Griseofulvin 
Antivirals Efavirenz 
Antiprotozoal Chloroquine,Metronidazole 
2. NON STEROIDAL 
ANTI-
INFLAMMATORY 
DRUGS 
 Paracetamol, Aspirin, 
Nimesulide, Mefenemic 
acid, Ibuprofen, Diclofenac 
3. ANTICONVULSANTS  Phenytoin, Sodium 
valproate, Carbamezapine, 
Phenobarbitone  
4. ANTIDEPRESSANTS  Imipramine 
5.  CANCER 
CHEMOTHERAPY 
 Imatinib mesylate 
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In our study the above five classes of drugs were encountered as shown in table 
6. A total of 108 [66.25%] cases due to antimicrobials were seen out of these 92 
cases were due to intake of antibacterials, 10 cases were due to antivirals, 5 
cases were due to antiprotozoal, single case was due to antifungal. 28 [17.17%] 
cases were due to Non steroidal anti-inflammatory drugs,25 [ 15.33%] cases 
were due to anticonvulsants and a single case[ 0.61%]each was due to 
antidepressants and chemotherapy. 
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8) Drugs commonly involved in ACDRs 
 
Table 7: Drugs commonly involved in ACDRs 
 
Sl No: Drugs No. of Cases Percentage % 
1. Cotrimoxazole 37 22.69 
2. Phenytoin 15 9.25 
3. Doxycycline 15 9.25 
4. Amoxycillin 13 7.97 
5. Paracetamol 10 6.13 
6. Nevirapine 9 5.55 
7. Ciprofloxacin 8 4.9 
8. Carbamezapine 6 3.68 
9. Cefixime 5 3.08 
10. Diclofenac 4 2.46 
11. Ibuprofen 4 2.46 
12. Penicillin 4 2.46 
13. Sodium valproate 3 1.85 
14. Piroxicam 3 1.85 
15. Aspirin 3 1.85 
16. Nimesulide 3 1.85 
17. Metronidazole 3 1.85 
18. Tetracycline 2 1.23 
19. Cefoperazone 2 1.23 
20. Chloroquine 2 1.23 
21. Isoniazid 2 1.23 
22. Norfloxacin 1 0.61 
23. Efavirenz 1 0.61 
24. Dapsone 1 0.61 
25. Mefenamic acid 1 0.61 
26. Phenobarbitone 1 0.61 
27. Imatinib mesylate 1 0.61 
28. Griseofulvin 1 0.61 
29. Imipramine 1 0.61 
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As shown in table 7  a total of 29 drugs were seen out of these cotrimoxazole 
was the most common drug causing ACDRs with 37 cases, second common 
drugs were phenytoin and doxycycline each involved in 15 cases, amoxicillin in 
13 cases, paracetamol in 10 cases, nevirapine in 9 cases, ciprofloxacin in 8 cases, 
carbamezapine in 6 cases, cefixime in 5 cases, diclofenac, ibuprofen and 
penicillin each in 4 cases, sodium valproate, piroxicam, aspirin, nimesulide and 
metronidazole each in 3 cases, Isoniazid, tetracycline, cefoperazone, chloroquine 
each in 2 cases, single cases were seen with dapsone, imipramine, griseofulvin, 
imatinib mesylate, phenobarbitone, mefenemic acid, norfloxacin, efavirenz. 
 
Figure 3: 
 
 
Others- Tetracycline, Cefoperazone, Nimesulide, Dapsone, Mefenemic acid, Aspirin,  Griseofulvin, 
Norfloxacin, Efavirenz, Imatinib mesylate, Chloroquine 
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9]Drugs and ACDRs caused by them:  
Table 8: Drugs and ACDRs caused by them 
 
(CTX- Cotrimoxazole, DOXY-Doxycycline, PHE- Phenytoin, AX- Amoxycillin, NVP-Nevirapine, PCM-
Paracetamol, CBZ-Carbamezapine, CPX-Ciprofloxacin, CFX-Cefixime, DIC-Diclofenac, IBP-Ibuprofen, SV-
Sodium valproate, PXM-Piroxicam.)  
As shown in table 8 it was observed that Cotrimoxazole was found to cause  
FDE in 26 cases, urticaria in 5 cases, urticaria with angioedema in 3 cases ,  SJS 
and EMF in a single case, Phenytoin was found to cause maculopapular rash in 8 
cases ,  DRESS in 5 cases,  TEN and SJS each in a single case.Amoxycillin was 
found to cause FDE in 9 cases, Urticaria, SJS, Erythroderma and Maculopapular 
rash each in a single case. Nevirapine in 2 cases of TEN, 3 cases of 
erythroderma,4 cases of maculopapular rash. Paracetamol was seen in 4 cases of 
FDE, 2cases each of urticaria, urticaria with angioedema & 1 case each of TEN 
& EMF: total of 10 cases.Carbamezapine  was seen in 2 cases each of FDE & 
Erythroderma and in 1 case each of TEN & SJS : total of 6 cases.Cefixime was 
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seen with 3 cases of FDE, 1 case each of Urticaria, DRESS & maculo- papular 
rash. Diclofenac sodium & Ibuprofen were associated with 4 cases each of FDE. 
Sodium valproate : 1 case of FDE, 2 cases of maculopapular rash, total of 3 
cases. Piroxicam : 2 cases of FDE , a case of urticaria :total of 3 cases. 
10) Site of involvement for common individual drugs in ACDRs: 
 
Table 9: Site of involvement for common individual drugs 
Sl No: Drugs Cutaneous 
involvement 
Both skin 
and 
mucosa 
Total Percentage 
% 
1. Cotrimoxazole 12 15 37 22.69 
2. Doxycycline 6 9 15 9.25 
3. Phenytoin 6 9 15 9.25 
4. Amoxycillin 6 7 13 7.9 
5. Paracetamol 6 4 10 6.13 
6. Nevirapine 3 6 9 5.55 
7. Carbamezapine 4 2 6 3.68 
8. Ciprofloxacin 7 1 8 4.9 
9. Cefixime 1 4 5 3.08 
10. Diclofenac 2 2 4 2.46 
11. Ibuprofen 2 2 4 2.46 
12. Sodium 
valproate 
2 1 3 1.85 
13 Piroxicam 2 1 3 1.85 
As shown in table 9 Cotrimoxazole was the most common drug causing 
cutaneous in12 and both involvement in 15 cases, followed by doxycycline and 
phenytoin each in 6 cases of cutaneous and 9 cases of both. Amoxycillin in 6 
cutaneous and both in 7 cases. Paracetamol in 6 cutaneous and both in 4 
cases.Nevirapine in 3 cutaneous cases and 6 of both cases. Carbamezapine in 4 
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cutaneous and 2 case of both. Ciprofloxacin in 7 cases of cutaneous and 1 case 
of both, Cefixime in 1 case of cutaneous and 4 cases of both, Diclofenac and 
Ibuprofen  each in 2 cases in both categories, Sodium valproate and Piroxicam 
each in 2 cases of cutaneous and 1 case of both skin and mucosal involvement.  
11)Associated diseases in ACDRs: 
Table 10 : Underlying associated diseases in ACDRs 
Associated disease No. of cases  
1. Upper respiratory tract infection 32(19.63%) 
2.Seizure disorder 24(14.72%) 
3. Fever & Headache 18(11.04%) 
4.HIV 10(6.13%) 
5. Lower respiratory tract infection 9(5.52%) 
6. Dental caries & Gingivitis 9(5.52%) 
7. Sinusitis 8(4.9%) 
8.Diabetes mellitus [DM]  7(4.29%) 
9.Hypertension [HTN] 6(3.68%) 
10. Urinary tract infection 6(3.68%)  
11.HTN+DM 4  (2.4%) 
12. Arthritis & Bursitis 4  (2.4%) 
13. Acute & Chronic suppurative otitis  
      media      
4  (2.4%) 
14. Tuberculous meningitis 3(1.84%) 
15. Malaria 3(1.84%) 
16. Acute diarrhea 3(1.84%) 
17. Typhoid 3(1.84%) 
18. Myalgia 3(1.84%) 
19. Pyoderma 2(1.22%) 
20.Leprosy 1  (0.61%) 
21. Depression 1  (0.61%) 
22. Chronic lymphocytic leukemia 1  (0.61%) 
23. Epididymoorchitis 1  (0.61%) 
24.External hordeolum 1  (0.61%) 
     TOTAL 163 
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As shown in table 10, maximum number of cases were seen with patients taking 
drugs for underlying upper respiratory tract infections: 32(19.63%), followed by 
seizure disorders 24(14.72%) cases, then followed by fever and headache 
18(11.04%) cases, HIV was seen in 10(6.13%) cases, equal no. of patients that is 
9(5.52%) cases were seen for both lower respiratory tract infections and dental 
caries & gingivitis. Among chronic long standing diseases Diabetes mellitus was 
seen in 7(4.29%) cases, Hypertension was seen in 6(3.68%) cases, both diabetes 
and hypertension were seen in 4(2.4%) cases. Urinary tract infections were seen 
in 6(3.68%) cases, 4(2.4%) cases each of arthritis and bursitis & acute and 
chronic suppurative otitis media were seen. 
3(1.84%) cases each of tuberculous meningitis, Malaria, acute diarrhea, myalgia 
& typhoid were seen. 2(1.22%) cases of pyoderma were seen. Single cases each 
of leprosy, depression, chronic lymphocytic leukemia, epididymoorchitis & 
external hordeolum were seen.  
 
12] Family history in ACDRs:  
       None of the cases had any history of family members with ACDRs. 
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DISCUSSION 
1) Incidence of ACDRs:  
Out of 1,03,536 total patients  during the study period of 2 years, 163 were 
diagnosed as ACDRs which constitutes 0.15%. The incidence of ACDRs has 
been found to be 2.6% in a study by chatterjee et al[42]  which is higher than our 
study 
2) Occurrence of various  clinical types of  ACDRs :  
The commonest ACDR in our study was FDE seen in 84 [51.53%] 
patients which is greater than a study by Thappa et al[3] where it was 28 [31.1%] 
patients. Maculopapular rash was seen in 15 [9.25%] patients in our study which 
is lesser than the study done by Thappa et al[3]  where it was 12.2%. Urticaria  
was seen in 15 [9.25%] patients in our study which is greater than in the study 
by Thappa et al [3]where it was 7.8% . Erythroderma in our study included 
11[6.74%] cases but according to Thappa et al[3] it was 3.3% which is lesser than 
our study.  Urticaria with angioedema constituted 10[6.17%] cases but Thappa et 
al[3]  recorded 1.1% which is lesser than our study. DRESS cases were 7 [4.32%] 
in number but in a study by Shear et al[41] 9% of cases were due to DRESS 
which is higher than our study.  SJS constituted 7[4.32%] cases , but was only 
3% in a study by Raksha MP et al[4]. TEN cases were 6 [3.7%] in number but 
only 1% in a study by Raksha MP et al[4] which is lesser than our study. EMF 
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cases were 5[3.08%] in our study but 6.7% in the study by Thappa et al[3] which 
is twice the number of cases when compared to our study. Acneiform eruptions 
were 2 [1.23%] in number whereas Thappa et al[3] recorded 3.3% which is 
greater than our study. 
3) Age distribution of various ACDRs:  
The age of the patients ranged from 3 months to 75 years. The majority of 
patients (33 patients or 20.24%) fall in the age group from 31-40 years followed 
by age group 41-50 years (32 patients or 19.63%). In a study by Ruchika 
Nandha et al [15] the maximum number of cases was seen in the age group 21-30 
years (25.27%) followed by the age group 31-40 years (23.07%) which is  
greater than our study. 
4) Gender distribution in ACDRs: 
   In our study, almost equal involvement was noted , 82 patients were 
males and 81 were females [male to female ratio was  1.01:1] out of 163 total 
cases , whereas during the study done by Ruchika Nandha et al[15] of the total 91 
cases reported 47 (51.7%) were females and 44 (48.3%) were males.  The male 
to female ratio was 0.93:1, which is slightly lesser than ours. 
Predominance of males was reported in few studies. Equal ratio has also been 
reported in other studies.[23] 
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  5)  Site of involvement in various types of ACDRs :  
Out of total 163 patients 84 [51.53%] cases had only cutaneous 
involvement without involving the mucosa but 79 [48.46%] cases had both skin 
and mucosal involvement. In patients having both skin and mucosal 
involvement, 47[59.49%] cases had oral mucosal involvement only, 5[6.32%] 
had genital mucosal involvement only & 27[57.44%] had both oral and genital 
mucosal involvement which is higher than in a study by Faisal et al[35] where 
about 32.7% of the patients (68/208) had mucosal involvement, the 
manifestations of which varied according to the type of rash. 
6) Recurrent episodes in various types of ACDRs :   
Out of 163 patients 76 [46.62%] patients had recurrent episodes which is 
higher than in a study by Thappa et al[3] where of the 90 consecutive patients, 25 
had consumed the same drug earlier, 13 had a similar cutaneous reaction earlier 
and 12 had no reactions . 
7) Various Drug classes involved in ACDRs:  
In our study the various drug classes encountered were: 
a] Antimicrobials : Cotrimoxazole, Amoxycillin , Ciprofloxacin ,  Nevirapine  , 
Cefixime ,Tetracycline, Cefoperazone, Griseofulvin, Norfloxacin, Efavirenz, 
Dapsone- 108 [66.25%] cases. 
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b] NSAIDs: Paracetamol, Diclofenac, Ibuprofen, Piroxicam, Aspirin,  
Nimesulide, Mefenemic acid-28 [17.17%] cases 
c] Anticonvulsants: Phenytoin, Carbamezapine, Sodium valproate-25 [15.33%] 
cases 
d] Antidepressants: Imipramine -1 [0.61%] case. 
e] Cancer chemotherapy: Imatinib mesylate-1 [0.61%] case. 
The common offending drug groups in a study by chatterjee et al[42]were 
antimicrobials (34.10%) which is lesser than our study, anticonvulsants 
(32.88%) which is higher than our study, anti-inflammatory drugs (21.51%) 
which is greater than our study.Similar incidence as in our study was seen with 
antidepressants and chemotherapy drugs. 
8) Drugs commonly involved in ACDRs : 
Commonest drug causing ACDR was Cotrimoxazole recorded in 37 cases, 
in a study by Vander Linden et al[19]the most frequent reactions were observed in 
patients receiving a trimethoprim-sulfonamide combination , which is similar to 
our study,followed by  Phenytoin and Doxycycline each in 15 (9.25%) cases, but 
Thappa et al[3] observed 7.8% cases for Phenytoin which is lesser than our study.  
Amoxycillin in 13 cases was the 3rd common drug but in a study by khushwaha 
et al[30] it was observed that amoxicillinwas 2ndmost common drug, Nevirapine  
in  9 cases, Paracetamol was involved in  10 cases and was the 5th commonest 
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drug in our study  but in a study by Naldi et al[30]  paracetamol was ranked at 
no.8 to cause ACDRs. Carbamezapine was the 6th commonest drug in our study 
which is in contrast to a study by Ding et al[29] where Carbamazepine was the 
most common drug causing severe ACDR. Ciprofloxacin  in  6 cases,  Cefixime 
in 5, Diclofenac in 4, Ibuprofen in 4, Sodium valproate , Metronidazole, 
Piroxicam,  Aspirin  & Nimesulide  in 3( 1.85%) cases each where as Thappa et 
al[3] recorded 2.2% for Metronidazole which is greater than our study. 
Tetracycline & Cefoperazone in 2 [1.23%] cases each. Mefenemic acid, 
Griseofulvin, Dapsone, Norfloxacin & Efavirenz each were incriminated in 
1[.61%] case, but in a study by  Thappa et al[3]  Griseofulvin was accounted for 
3.3% cases, which is much greater than our study. 
9)  Drugs and ACDRs caused by them: 
 
a) Cotrimoxazole was found to cause FDE in 26 cases,urticaria in 5 cases, 
urticaria with angioedema in 3 cases ,  SJS and EMF in a single case.In a study 
by Thappa et al[3] Cotrimoxazole was the leading causative agent (29.5%) in 
FDE cases which is consistent with our study. 
b) Phenytoin was found to cause maculopapular rash in 8 cases, DRESS in 5 
cases, TEN and SJS each in a single case whereas in a study by Noel et al[34] 
phenytoin caused maximum no of cases of Maculopapular rash followed by 
TEN and erythroderma. 
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c) Amoxycillin was found to cause FDE in 9 cases, Urticaria, SJS, Erythroderma 
and Maculopapular rash each in a single case, whereas in a study by S Ghosh et 
al[30], the drug which was attributed to cause maximal number of maculopapular 
rashes, was amoxicillin. 
d) Nevirapine was implicated in 2 cases of TEN, 3 cases of erythroderma,4 cases 
of maculopapular rash: total of 9 cases, wheras in a study by Ananworanich et 
al[32] nevirapine most commonly caused maculopapular rash ,TEN. 
e) Paracetamol was seen in 4 cases of FDE, 2cases each of urticaria, urticaria 
with angioedema & 1 case each of TEN & EMF: total of 10 cases. 
Noel et al[34] recorded 2 cases of urticaria , 1 case each of FDE and SJS, which is 
lesser than our study. 
f) Carbamezapine was seen in 2 cases each of FDE & Erythroderma and in 1 
case each of TEN & SJS: total of 6 cases, whereas in a study by Hung et al[31] 
the anticonvulsant carbamazepine (CBZ) frequently causes adverse cutaneous 
drug reactions (ACDRs), including maculopapular eruption (MPE), 
hypersensitivity syndrome (HSS), Stevens-Johnson syndrome (SJS) and toxic 
epidermal necrolysis (TEN). 
g) Cefixime was seen with 3 cases of FDE, 1 case each of Urticaria, DRESS & 
maculopapular rash whereas in a study by Shipley et al Cefixime caused 
urticaria more frequently.[39] 
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h) Diclofenac sodium & Ibuprofen were associated with 4 cases each of FDE 
which is consistent with a study by Stern S et al where similar incidence was 
found.[37] 
i) Sodium valproate : 1 case of FDE, 2 cases of maculopapular rash, total of 3 
cases, whereas in a study by Patricia et al[38]there were no confirmed serious 
cutaneous diagnoses in 1,504 new valproate users. 
j) Piroxicam : 2 cases of FDE , a case of urticaria :total of 3 cases, whereas in a 
study by Stern S et al[37] Piroxicam was seen to cause TEN. 
10) Site of involvement for  common individual drugs in ACDRs: 
Cotrimoxazole was the most common drug causing cutaneous in 12 and 
both involvement in 15 cases, which is similar to a study by Arora et al[27], 
followed by doxycycline and phenytoin each in 6 cases of cutaneous and 9 cases 
of both. Amoxycillin in 6 cutaneous and both in 7 cases. Paracetamol in 6 
cutaneous and both in 4 cases.Nevirapine in 3 cutaneous cases and 6 of both 
cases. Carbamezapine in 4 cutaneous and 2 case of both. Ciprofloxacin in 7 
cases of cutaneous and 1 case of both, Cefixime in 1 case of cutaneous and 4 
cases of both, Diclofenac and Ibuprofen  each in 2 cases in both categories, 
Sodium valproate and Piroxicam each in 2 cases of cutaneous and 1 case of both 
skin and mucosal involvement. Specfic references involving cutaneous and 
mucosal involvement for other drugs were not found. 
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11) Associated diseases in ACDRs: 
Maximum number of cases were seen with patients taking drugs for 
underlying upper respiratory tract infections; 32(19.63%), followed by seizure 
disorders 24(14.72%) cases, then followed by fever and headache 18(11.04%) 
cases, HIV was seen in 10(6.13%) cases, equal no. of patients that is 9(5.52%) 
cases were seen for both lower respiratory tract infections and dental caries and 
gingivitis.  
Among chronic long standing diseases Diabetes mellitus was seen in 
7(4.29%) cases, Hypertension was seen in 6(3.68%) cases; both diabetes and 
hypertension were seen in 4(2.4%) cases. Urinary tract infections were seen in 
6(3.68%) cases, 4(2.4%) cases each of arthritis and bursitis & acute and chronic 
suppurative otitis media were seen. 
3(1.84%) cases each of tuberculous meningitis, Malaria, acute diarrhea, myalgia 
& typhoid were seen. 2(1.22%) cases of pyoderma were seen. Single cases each 
of leprosy, depression, chronic lymphocytic leukemia, epididymoorchitis & 
external hordeolum were seen.  
In a study by Thappa et al[3]  history of a previous systemic illness was 
present in 44 patients (48.9%); 12 (13.3%) had a major illness while the 
remaining 32 (35.6%) had a minor one. 
Hachem et al[18] reported an incidence of 12% of drug-related rashes among 85 
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HIV-infected patients which is greater than that found in our study.  
12) Family history in ACDRs: 
None of the patients in our study had a positive family history whereas 
according to a recently published study of ACDR during a 5year period by 
Fernandez et al[16], the risk for developing an adverse cutaneous reaction to 
drugs in patients with a positive family history for these reactions is 14% 
compared to 1.2% for those without a family history. In this study only 23% of 
the patients with an ACDR had a positive personal or family history. 
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SUMMARY 
1) Incidence: 
 Out of all patients attending SKIN OPD during the study period of 24 
months 163 patients were diagnosed with ACDR, which  constituted  to 0.15 %.  
 
2) Occurrence of various  clinical types of  ACDRs :  
 Out of the total 163 patients FDE was the most common ACDR seen in 84 
cases, Urticaria and  Maculopapular rash in 15 cases each, Erythroderma in 11 
cases, Urticaria with angioedema in 10 cases, DRESS  & SJS in 7 cases, TEN in 
6 patients, EMF in 5 patients, Acneiform eruptions in 2 cases and a single case 
of phototoxic reaction. 
 
3) Age distribution in various ACDRs:  
  The maximum no. of cases that is 39.87% of patients were falling between 
31-50 years of age group. The youngest patient was 3 months old & oldest 
patient was 75 years. 
 
4) Gender distribution in ACDRs: 
 An almost equal incidence of occurrence in both males & females was 
noted, with a slight male predominance.82 cases were males & 81 cases were 
females.  
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5) Site of involvement in various types of ACDRs : 
84 patients had only cutaneous involvement.Both cutaneous and mucosal 
involvement was seen in 79 out of 163 patients. Out of these 49 had oral 
mucosal involvement only, 5 had  genital mucosal involvement only, 24 had 
both oral and genital mucosal involvement.  
 
6) Recurrent episodes in various types of ACDRs:  
 Recurrent episodes were seen in 76 patients out of 163. DRESS, TEN, 
Erythroderma, Acneiform eruption and phototoxic reaction patients never had 
any previous episodes of recurrences. 
 
7] Various drug classes involved in ACDRs:  
The commonest drug class involved was antimicrobials with 11 drugs, 
followed by NSAIDs with 7 drugs, next common was anticonvulsants with 3 
drugs and least common was seen with antidepressants and cancer chemotherapy 
with a single drug. 
 
8) Drugs commonly involved in ACDRs:  
 Cotrimoxazole was the commonest drug causing ACDR which was found 
in 37 cases followed by  Phenytoin and Doxycycline in 15 cases each, 
Amoxycillin in 13cases , Paracetamol  in  10 cases , Nevirapine  in  9 cases , 
Ciprofloxacin  in  8 cases,  Carbamezapine in 6 cases, Cefixime in 5 cases, 
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Diclofenac, penicillin and Ibuprofen in 4 cases each, Sodium valproate , 
Piroxicam , Aspirin ,Metronidazole& Nimesulide  in 3 cases each. Tetracycline, 
Chloroquine, Isoniazid & Cefoperazone in 2 cases each. Mefenemic acid, 
Griseofulvin, Norfloxacin, Dapsone, Phenobarbitone, Imipramine, Imatinib 
mesylate & Efavirenz each were incriminated in 1 case each. 
 
9)  Drugs and ACDRs caused by them: 
Cotrimoxazole was found in 26 FDE cases, 5 cases of urticaria, 3 cases of 
urticaria with angioedema, 1 case each of SJS and EMF.Phenytoin in 8 cases of 
maculopapular rash , 5 cases of DRESS, 1 case of TEN, 1 case of 
SJS.Amoxycillin was seen in 9 cases of FDE, 1 case each of urticaria, SJS, 
Erythroderma, Maculopapular rash.Nevirapine was implicated in 2 cases of 
TEN, 3 cases of erythroderma,4 cases of maculopapular rash.Paracetamol was 
seen in 2 cases each of FDE, urticaria, urticaria with angioedema & 1 case each 
of TEN & EMF.Carbamezapine  was seen in 2 cases each of FDE & 
Erythroderma and in 1 case each of TEN & SJS .Cefixime was seen with 3 cases 
of FDE, 1 case each of Urticaria, DRESS & maculopapular rash.Diclofenac 
sodium & Ibuprofen were associated with 4 cases each of FDE.Sodium 
valproate : 1 case of FDE, 2 cases of maculopapular rash, total of 3 
cases.Piroxicam : 2 cases of FDE ,a case of urticaria . 
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10) Site of involvement for common individual drugs: 
Cotrimoxazole was the most common drug causing cutaneous in 12 and 
both involvement in 15 cases, followed by doxycycline and phenytoin each in 6 
cases of cutaneous and 9 cases of both. Amoxycillin  in 6 cutaneous and both in 
7 cases. Paracetamol in 6 cutaneous and both in 4 cases.Nevirapine in 3 
cutaneous cases and 6 of both cases. Carbamezapine in 4 cutaneous and 2 case 
of both. Ciprofloxacin in 7 cases of cutaneous and 1 case of both, Cefixime in 1 
case of cutaneous and 4 cases of both, Diclofenac and Ibuprofen  each in 2 cases 
in both categories, Sodium valproate and Piroxicam each in 2 cases of cutaneous 
and 1 case of both skin and mucosal involvement.  
11) Associated diseases in ACDRs: 
Maximum number of cases were seen with patients taking drugs for 
underlying upper respiratory tract infections; 32(19.63%), followed by seizure 
disorders 24(14.72%) cases, then followed by fever and headache 18(11.04%) 
cases, HIV was seen in 10(6.13%) cases, equal no. of patients that is 9(5.52%) 
cases were seen for both lower respiratory tract infections and dental caries & 
gingivitis. Among chronic long standing diseases Diabetes mellitus was seen in 
7(4.29%) cases, Hypertension was seen in 6(3.68%) cases, both diabetes and 
hypertension were seen in 4(2.4%) cases. Urinary tract infections were seen in 
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6(3.68%) cases, 4(2.4%) cases each of arthritis and bursitis & acute and chronic 
suppurative otitis media were seen. 
3(1.84%) cases each of  tuberculous meningitis, malaria, acute diarrhea, myalgia 
& typhoid were seen. 2(1.22%) cases of pyoderma were seen. Single cases each 
of leprosy, depression, chronic lymphocytic leukemia, epididymoorchitis & 
external hordeolum were seen.  
 
12) Family history in ACDRs: 
There was no positive family history in any of the cases. 
 
 
 
 
 
 
 
 
 
 
 
 
81 
 
CONCLUSION 
 A total of 163 patients out of 1,03,536 were diagnosed with ACDRs. The 
incidence of Cutaneous adverse drug reaction in this study was 0.15% during 
this study period of 2 years. 
 Maximum number of the patients were in the 4thand 5th decade, closely 
followed by patients in 1st and 3rd decades.Both the genders were almost equally 
involved with a slight predominance of male patients.  
 Fixed drug eruption was the commonest type of ACDR followed by Urticaria 
and Maculopapular rash, next closely followed by erythroderma . 
Out of all the ACDRs 84 cases had exclusive cutaneous involvement only. Both 
skin and mucosa were involved in rest of the 79 cases. Out of these 79 cases 47 
had only oral mucosal involvement, 5 had genital mucosal involvement only and 
27 had both the mucosa involved.  Recurrent episodes were seen in 76 patients 
of all the total cases. 
 The commonest class of drug causing ACDR was antimicrobials, among 
these antimicrobials antibacterials were the commonest subclass involved. Non 
steroidal anti-inflammatory drugs were the second commonest followed by 
anticonvulsants. Other groups which caused ACDR were antidepressants and 
cancer chemotherapy. 
 Amongst all the drugs Cotrimoxazole was the commonest drug causing 
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ACDR followed by equal involvement of phenytoin and doxycycline . 
 Among the individual ACDRs, FDE was most commonly caused by 
Cotrimoxazole. Mucosal involvement was most commonly seen with 
Cotrimoxazole followed by Phenytoin and doxycycline in succession. None of 
the patients had a positive family history of drug reaction.  
  Upper respiratory tract infection was the most common underlying 
systemic disorder following which patients had consumed the drug and 
developed ACDR. 
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PROFORMA 
Name: 
Age: 
Gender : 
Address: 
DETAILS ABOUT THE PRESENTING CONDITION: 
-Time  elapsed  between  drug   intake  &  onset  of  first  sign/symptom: 
-Time  since  onset  of  first  sign/symptom: 
-Type  of  lesion  patient  developed: 
-Presence  of  mucosal  involvement: 
ABOUT  THE  DRUG: 
-Probable drug  which  caused  the  onset: 
-Mode  of  drug  administration: 
-Type  of  drug  taken[allopathic/homeopathic/ayurvedic]: 
-Nature  of  illness  for  which  drug  was  taken: 
-Total  number  of  dose  of  drug  taken: 
-Any  previous  h/o  drug  interactions: 
-Whether  taken  over  the  counter/prescribed  by RMP: 
-Precipitating  factors  if  any: 
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CONTRIBUTORY  FACTORS: 
-Any  associated  systemic  illness: 
-If  the  drug  was  taken  for  systemic  illness: 
-Any  family  h/o  drug  interactions: 
-Associated  secondary  complications: 
-Scalp/hair/nail  involvement: 
-Similar  episodes  in  the  past: 
-If  yes  then  details  about  the condition: 
-Extracutaneous  manifestations: 
-HIV  status  of  the  patient: 
DERMATOLOGICAL  EXAMINATION: 
 
SYSTEMIC  EXAMINATION: 
CVS: 
RS: 
P/A: 
CNS:  
RELEVANT  INVESTIGATIONS  CARRIED  OUT: 
Complete  hemogram: 
Liver  function  test: 
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Renal  function  test: 
Tzanck  smear: 
FINAL  DIAGNOSIS: 
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KEY TO MASTER CHART: 
 
FDE  -  Fixed Drug Eruption 
SJS  -  Steven Johnson Syndrome 
TEN  -  Toxic Epidermal Necrolysis 
DRESS - Drug Rash with Eosinophilia and Systemic Symptoms     
ASOM -  Acute Suppurative Otitis Media 
CSOM - Chronic Suppurative Otitis Media 
HTN  - Hypertension 
DM  - Diabetes Mellitus 
H+D  -  Hypertension+ Diabetes mellitus 
LRI  - Lower respiratory tract infection 
TB MEN - Tuberculous meningitis 
AIDS  - Acquired Immunodeficiency Syndrome 
CLL  - Chronic lymphocytic leukemia 
ATT  - Antituberculous treatment 
UTI  - Urinary tract infection 
HIV  - Human immunodeficiency virus 
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A CLINICOEPIDEMIOLOGICAL STUDY ON ADVERSE 
CUTANEOUS DRUG REACTIONS 
INTRODUCTION:An adverse drug reaction (ADR) may be defined as an 
undesirable clinical manifestation resulting from administration of a particular 
drug; this includes reactions due to overdose, predictable side effects and 
unanticipated adverse manifestations. 
Very few published studies have assessed the epidemiological and clinical 
features of drug reactions in India and still fewer in South India. Hence this 
study was undertaken to assess the pattern and clinical features of ACDRs in 
South Tamilnadu. 
AIM OF THE STUDY: 
1. To study the clinicoepidemiological pattern of various adverse cutaneous 
drug reactions in patients attending SKIN OPD, Government Rajaji Hospital. 
2. To study the common drugs causing adverse cutaneous drug reactions. 
MATERIALS AND METHODS: 
This study was conducted at the skin OPD, Government Rajaji Hospital, 
Madurai Medical College, Madurai during the period from October 2009-
September 2011 [24 months].All consecutive consenting patients diagnosed 
clinically as a case of ACDR of all age groups, of all genders were included in 
the study. 
RESULTS AND CONCLUSION: 
A total of 163 patients out of 1,03,536 were diagnosed with ACDRs. 
Maximum number of the patients were in the 4thand 5th decade. Fixed drug 
eruption was the commonest type of ACDR followed by Urticaria and 
Maculopapular rash, next closely followed by erythroderma . Out of all the 
ACDRs 84 cases had exclusive cutaneous involvement only. Both skin and 
mucosa were involved in rest of the 79 cases. The commonest class of drug 
causing ACDR was antimicrobials. Other classes were anticonvulsants, 
NSAIDs, antidepressants & cancer chemotherapy.Cotrimoxazole was the 
commonest drug causing ACDR. Among the individual ACDRs, FDE was 
most commonly caused by Cotrimoxazole. Among the individual ACDRs, 
FDE was most commonly caused by Cotrimoxazole. Mucosal involvement 
was most commonly seen with Cotrimoxazole followed by Phenytoin and 
doxycycline in succession. Mucosal involvement was most commonly seen 
with Cotrimoxazole. None of the patients had a positive family history of 
ACDR.  
Upper respiratory tract infection was the most common underlying systemic 
disorder following which patients had consumed the drug and developed 
ACDR. 
Key words: ACDRs, Fixed Drug Eruption, Cotrimoxazole. 
  
 
 
 
 
 
 
 
 
S.No NAME AGE GENDER DIAGNOSIS DRUG
RECURRENT 
EPISODES  MUCOSA
DURATION 
BETWEEN 
DRUG INTAKE 
& DISEASE 
ONSET DISEASE ASSOCIATION
1 Chellapandi 37 M urt+angioedema Paracetamol nil oral  1hr fever+headache
2 Poomathy  12 F urticaria  Chloroquine nil nil 0.5hr malaria
3 Ayyappa 35 M urticaria  Griseofulvin nil nil 12hr URI
4 Angela 9 F bullous FDE Cotrimoxazole 2 nil 1hr URI
5 M.Ganesan 20 M EMF Cotrimoxazole nil oral+ genital 2d URI
6 Anand 11 M FDE Cotrimoxazole nil oral 12hr URI
7 Rathna 40 F bullous+nonbullous FDEAmoxycillin 1 oral 1hr Sinusitis
8 Sagairaju 47 M FDE Cotrimoxazole 1 oral 1hr URI
9 Gouri 11 F FDE Diclofenac nil nil 1hr Myalgia
10 Fathima 45 F FDE Amoxycillin 3 nil 12hr Sinusitis
11 Arjun 5 M FDE Diclofenac nil genital 1hr Myalgia
12 Amaravathi  35 F FDE Cotrimoxazole nil oral 15min URI
13 Veershanmathi 6mo F FDE Cotrimoxazole nil nil 1day fever 
14 Aadhavan 19 M bullous+nonbullousFDE Ciprofloxacin nil nil 12hr Acute Diarrheoa
15 Puspa 38 F FDE Sodium valproatenil nil 12hr seizure disorder
16 Khathija 50 F bullous FDE Amoxycillin 5 oral 2hr HTN
17 V Raman 30 M FDE Tetracycline 4 genital 12hr dental caries
18 Thiruvasanan 44 M FDE paracetamol many genital 2hr fever 
19 Bharathi 26 M FDE Ciprofloxacin 1 genital+oral 2hr typhoid
20 Suguna 18 F FDE Amoxycillin nil nil 6hr External hordeolum
21 Chinnan 40 M FDE Piroxicam 1 only genital 2d epididymoorchitis
22 Dhanalakshmi 31 F FDE metronidazole 2 oral 6hr Acute Diarrheoa
23 S Pandi 17 M FDE Amoxycillin 2 oral 12hr Sinusitis
24 Nahur Aniba 30 M FDE Doxycycline 4 genital+oral 1hr dental caries
25 Seethalakshmi 20 F phototoxic rxn Ciprofloxacin nil nil 3d Gingivitis
MASTER CHART
26 Sanjay 1.5 M maculopapular rash phenytoin nil oral 3 weeks seizure disor
27 Gnanamoorthy 50 M DRESS phenytoin nil nil 4 weeks TB MEN
28 Haridhas 10 M erythroderma Paracetamol nil nil 7d fever 
29 Vasanth 10 M TEN phenobarbitone nil genital+oral 8d seizure disorder
30 Muthalai 35 F maculopapular rash Nevirapine nil nil 3 weeks AIDS
31 Sanjay 1.5 M DRESS phenytoin nil oral 3 weeks seizure disorder
32 Janaranjini 9 F DRESS cefixime nil oral 3 weeks LRI
33 Vijayan 55 M FDE cotrimoxazole 3 nil 12hr URI
34 Prema 42 F bullous FDE cotrimoxazole 3 nil 1day URI
35 Vairmani 13 F FDE cotrimoxazole many nil 6hr URI
36 Selvapandi 75 M bullous FDE amoxycillin nil nil 6hr DM
37 Mayandi 50 M FDE Ibuprofen 3 nil 4hr DM
38 Maradupandi 30 M DRESS phenytoin nil oral 3 weeks seizure disorder
39 Jeeva 11 M bullous FDE cotrimoxazole nil nil 6hr URI
40 Arulmary 32 F SJS cefoperazone 10 genital+oral 48hr LRI
41 Chandra 55 F erythroderma Imatinib mesylatenil nil 2d CLL
42 Bhagyam 34 F maculopapular rash nevirapine nil oral 16d AIDS
43 Adiraja 19 M TEN norfloxacin nil oral 24hr UTI
44 Nandini 14 F Urticaria mefenemic acid nil nil 2hr fever+headache
45 Joshua 6 M SJS carbamezapine nil oral 1day Absent seizures
46 Mookammal 46 F EMF minor paracetamol nil oral 15day fever 
47 Govindan 25 M SJS cotrimoxazole nil oral 1day URI
48 Mariyammal 59 F FDE cotrimoxazole 4 oral 2days DM
49 Vijaya 30 F FDE doxycycline many nil 6hr UTI
50 M.Malliga 45 F maculopapular rash phenytoin nil nil 24days seizure disorder
51 Kasthuri 30 F bullous FDE doxycycline nil nil 4days dental caries
52 Shanthi 35 F Urticaria paracetamol nil nil 4hr fever 
53 Mayila 56 F maculopapular rash efavirenz nil nil 3days HIV
54 Mohan 34 M maculopapular rash ciprofloxacin nil nil 12hr typhoid
55 Varadharaj 26 M maculopapular rash phenytoin nil nil 3 weeks seizure disorder
56 Prema 33 F mucosal FDE cotrimoxazole 3 oral 6hrs URI
57 Raju 43 M FDE carbamezapine 6 nil 6hrs Absent seizures
58 Saravana kumar 26 M bullous FDE doxycycline 1 nil 12hr dental caries
59 Petchi 47 F SJS cefixime 2 oral+ genital 1hr LRI
60 Valarmathy 28 F urt+angioedema cotrimoxazole nil oral 6hrs URI
61 Bose 50 M erythroderma nevirapine nil oral 10days AIDS
62 Muneeswari 40 F urt+angioedema penicillin 2 oral 2hr fever 
63 Kamakshi 55 F bullous FDE Doxycycline nil nil 3days DM
64 Ravi 48 M FDE Ibuprofen 6 oral+ genital 30 minutes Arthritis
65 Gopal 65 M FDE cotrimoxazole 1 nil 3days HTN
66 Palaneeswari 60 F FDE Cotrimoxazole 3 nil 1hr DM
67 Nithish  1.5 M FDE cotrimoxazole nil oral  24hr URI
68 K Sundareswari 48 F FDE doxycycline 2 oral  30 minutes UTI
69 Sumathy 38 F FDE doxycycline 3 oral+ genital 4hr dental caries
70 Chandrakala 37 F bullous FDE doxycycline 3 nil 12hr Pyoderma
71 Selvarani 25 F FDE Amoxycillin 2 oral  3hours Sinusitis
72 Alagu 45 F bullous FDE cotrimoxazole 3 nil 1 day URI
73 Premkumar 9 M FDE cefpodoxime 1 oral 24hr LRI
74 Sivamurugan 4 M bullous FDE cefixime 3 nil 2 days LRI
75 Raghukumar 6 M  FDE penicillin nil nil 2hr Pyoderma
76 R Jagadeesan 29 M  bullous FDE nimesulide nil  nil  12hr Arthritis
77 Chandra  35 F FDE piroxicam 3 nil  3days fever 
78 Tamilarasi 55 F FDE doxycycline 2 oral 1 day HTN
79 Aruldas 12 M  FDE nimesulide many  nil 1week fever 
80 Sivagami  65 F FDE ciprofloxacin 1 nil  2 days DM
81 Rajasekaran 41 M  FDE doxycycline nil  oral 12hr URI
82 Manikanthan 20 M  bullous FDE cotrimoxazole many nil  1 day URI
83 Solai 55 F bullous FDE nimesulide many nil  5 days HTN
84 Vijaya 32 F erythroderma nevirapine nil  oral 2 weeks AIDS
85 Ponnammal 57 F Urticaria cotrimoxazole 2 nil  2 days HTN
86 Sathya 6 F EMF Amoxycillin nil  oral+ genital 3days URI
87 Savithri K S  52 F erythroderma nevirapine nil  oral 3 weeks AIDS
88 Janaranjini  6 F DRESS cefoperazone nil  oral  2 weeks LRI
89 Amutha 24 F maculopapular rash phenytoin 2 oral 1 month seizure disorder
90 Prakash 35 M  SJS phenytoin nil  oral+ genital 15 days seizure disorder
91 Rathna 50 F urt+angioedema cotrimoxazole nil  oral 12hr URI
92 Lokanathan 25 M  Urticaria ciprofloxacin nil  nil  4hr typhoid
93 Panneer selvam 52 M  erythroderma carbamezapine nil  nil  1 month seizure disorder
94 Nagarani 20 F acneiform eruptions ATT  nil  nil  3 months TB MEN
95 Prabhakar 21 M  acneiform eruptions ATT  nil  nil  20 days  TB MEN
96 Azhagar Raj 48 M  Urticaria cotrimoxazole nil  nil  4hr URI
97 Kashi 70 M  Urticaria metronidazole nil  nil  6hr H+D
98 Pandi  36 M  urt+angioedema doxycycline nil  oral+ genital 1hr dental caries
99 Eswari 17 F DRESS phenytoin nil  oral  2 weeks seizure disorder
100 Amaravathi  38 F FDE paracetamol nil  nil 3hours fever 
101 Mahalingam 65 M  FDE ibuprofen nil  nil 30 minutes H+D
102 Mohan 47 M  FDE cotrimoxazole many oral+ genital 2hr URI
103 Dinesh 22 M  FDE ciprofloxacin 3 nil  3days Sinusitis
104 Kavitha 25 F FDE amoxycillin nil  nil  2 days ASOM
105 Pasupathi 25 M  SJS cefixime nil  oral+ genital 2 days LRI
106 Panju 43 F erythroderma sodium valproate nil  oral 2 months seizure disorder
107 Ayyanar 60 M  urticaria piroxicam 3 nil  3hours H+D
108 Chinnakani 40 M  TEN phenytoin nil  oral+ genital 1 month seizure disorder
109 Anushya 17 F FDE penicillin 3 nil  3hours URI
110 Mani  40 F bullous FDE cotrimoxazole 4 oral 6hrs URI
111 Syed Ibrahim 40 M  bullous FDE doxycycline 2 oral 7 hours dental caries
112 Parvathi 24 F erythroderma chlorpromazine nil  nil  1 month seizure disorder
113 Vijaya 32 F FDE cotrimoxazole 6 nil  4hr URI
114 Sumathy 30 F maculopapular rash phenytoin nil  oral 4 weeks seizure disorder
115 Ammani  6 F Urticaria chloroquine nil  nil  2hr malaria
116 Alagammal 23 F Urticaria Amoxycillin 4 nil  4hr ASOM
117 Backiaraja 32 M  maculopapular rash phenytoin nil  nil  3 weeks seizure disorder
118 Duraiammal 34 F urt+angioedema metronidazole 3 oral+ genital 4hr Acute Diarrheoa
119 Eswar  45 M  erythroderma sodium valproate nil  nil  6 weeks seizure disorder
120 Thirupathy 16 M  FDE cotrimoxazole many oral  4hr URI
121 T K Ramesh 41 M  FDE Amoxycillin nil  nil  5 hours Sinusitis
122 Vishith 13 M  FDE cotrimoxazole 3 nil  6hrs URI
123 Seema 10 F bullous FDE cotrimoxazole 4 oral  12hr URI
124 Saraswathi 47 F FDE cotrimoxazole 2 nil 30 minutes fever 
125 Murugan 37 M  FDE NSAIDs 6 oral  2hr fever 
126 Ayyava  30 M  FDE cotrimoxazole 3 oral  8 hours URI
127 Praveen 36 M  Urticaria paracetamol many nil  6hrs fever+headache
128 Waheeda banu 32 F urt+angioedema ciprofloxacin 4 oral  8 hours UTI
129 Latha 25 F maculopapular rash phenytoin nil  nil  3 weeks seizure disorder
130 Umapathy 53 M  erythroderma carbamezapine nil  nil  2 months seizure disorder
131 Sitalakshmi 45 F urt+angioedema cefixime 4 oral+ genital 3hours LRI
132 Kannan 56 M  EMF Tetracycline many oral 6hrs CSOM
133 Vasanthi 45 F erythroderma dapsone nil  nil  2 months leprosy
134 Bhuvaneswari 65 F DRESS phenytoin nil  nil  4 weeks seizure disorder
135 Chinnakalai 45 M  Urticaria Imipramine 6 nil  5 hours Depression
136 Asoka 32 M  FDE cotrimoxazole 2 nil  4hr UTI
137 Thiyagaraj 43 M  maculopapular rash nevirapine nil  nil  2 weeks HIV
138 Pavan 28 M  EMF penicillin many  oral+ genital 48hr Sinusitis
139 Sangilikalai 54 M  Urticaria cotrimoxazole many  nil  12hr LRI
140 Pandiarajan 34 M  FDE Aspirin 3 nil  1hr fever+headache
141 Visheeth 16 M  FDE cotrimoxazole nil  genital 2hr URI
142 Sooryabiwi 60 F FDE doxycycline 4 oral  30 minutes UTI
143 Krishnan 26 M  SJS Amoxycillin nil  oral+ genital 3hours Sinusitis
144 Chinnasamy 30 M  bullous FDE doxycycline nil  oral 12hr dental caries
145 Abdul Rahman 30 M  maculopapular rash Amoxycillin nil  nil  1 day fever 
146 Lakshmi 23 F bullous FDE ibuprofen nil  oral 4hr Myalgia
147 Thiyagaraja 7 M  FDE aspirin nil  nil  7 hours fever 
148 Seethalakshmi 50 F bullous+nonbullous FDE cotrimoxazole many oral+ genital 2hr URI
149 Lakshmi 28 F bullous FDE diclofenac 3 oral 3hours bursitis
150 Sokkar 57 M  FDE Aspirin 4 nil  4hr Arthritis
151 prema 42 F  FDE doxycycline 2 nil  5 hours CSOM
152 Md Ibrahim 1 M  FDE paracetamol nil  nil  2 days fever 
153 Ponnuthai 67 F  Urticaria cotrimoxazole many  nil  4hr HTN
154 Panchavarnan 55 F   bullous FDE diclofenac 4 nil  4hr DM
155 Vijaylakshmi 45 F  FDE cotrimoxazole many nil  2hr URI
156 Rashida Biwi 53 F  urt+angioedema paracetamol many  oral+ genital 2hr H+D
157 Vedavyas 14 M  TEN  carbamezapine nil  oral+ genital 8 hours seizure disorder
158 Samudram 45 M  maculopapular rash phenytoin nil  oral 3 weeks seizure disorder
159 Thangam 46 M  maculopapular rash nevirapine nil  nil  12hr AIDS
160 Devanand 10 M  FDE carbamezapine ni.  nil  12hr Absent seizures
161 Kruthika 3 F  urt+ angioedema cotrimoxazole nil  oral 12hr URI
162 Valli 32 F  TEN  nevirapine nil  oral+ genital 10days AIDS
163 Mridula 52 F  TEN  nevirapine nil  oral+ genital 5 days AIDS
